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DISCOVERY OF NOVEL UBIQUITIN- AND METHYLATION-DEPENDENT INTERACTIONS 
USING PROTEIN DOMAIN MICROARRAYS 
Jianji Chen, M.S. 
Advisory Professor: Mark T. Bedford, Ph.D. 
Post-translational modifications (PTMs) drive signal transduction by interacting with "reader" 
proteins. Protein domain microarray is a high throughput platform to identify novel readers for 
PTMs. In this dissertation, I applied two protein domain microarrays identifying novel readers 
for histone H2Aub1 and H2Bub1, and H3TM K4me3. Ubiquitinations of histone H2A at K119 
(H2Aub1) and histone H2B at K120 (H2Bub1) function in distinct transcription regulation and 
DNA damage repair pathways, likely mediated by specific "reader" proteins. There are only 
two H2Aub1-specific readers identified and no known H2Bub1-specific readers. Using a 
ubiquitin-binding domain microarray, I discovered the phospholipase A2-activating protein 
(PLAA) PFU domain as a novel H2Bub1-specific reader. PFU domain interacts with H2Bub1 
in the context of histone acid extracts but not recombinant nucleosomes, suggesting that 
PLAA may require additional partners for chromatin binding or PLAA only interacts with free 
H2Bub1. PLAA knockout cells show decreased H2Aub1 and H2Bub1, and an accumulation 
of a 15 kDa ubiquitin-like protein in the cytoplasm. PLAA co-localizes with laser 
microirradiation-induced DNA damage sites, suggesting PLAA's function in DNA damage 
repair. PHD fingers recognize the histone H3 N-terminal tail harboring either H3K4me3 or 
H3K4me0. Structural studies have identified common features among different H3K4me3 
effector PHDs: Cleaved initiator methionine: a groove that fits the R2 residue, and an aromatic 
cage that engages the K4me3. We hypothesize that some PHDs engage with non-histone 
ligands whose N-termini adhere to the three rules. A search of the human proteome revealed 
a striking enrichment of chromatin-binding proteins, and we termed these H3 N-terminal 
mimicry proteins (H3TMs). We selected seven H3TMs and synthesized the methylated forms 
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of their N-termini. Using a methyl reader microarray, we found that they can bind known PHD 
and Tudor H3K4me3 effector proteins. We focused on the interaction between the kinase 
VRK1 and the PHF2 PHD domain. Several H3TMs peptides, in their unmethylated form, 
interact with NuRD complex components. These findings provide in vitro evidence that 
methylation of H3TMs can promote novel interactions with PHD finger- and Tudor domain-
containing proteins and block interactions with the NuRD complex. We propose that these 
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CHAPTER 1 INTRODUCTION 
1.1 PROTEIN-PROTEIN INTERACTIONS 
1.1.1 Functional significance 
DNA, RNA, and protein are three information-carrying biomolecules that constitute the central 
dogma of molecular biology (Crick, 1970). Carrying the genetic information from DNA and 
RNA, protein is the workhorse molecule in all living organisms. Proteins have three primary 
cellular functions, catalyzing chemical reactions as enzymes, transducing molecular signaling 
as ligand binders, and forming subcellular structures as building blocks. Execution of protein 
function relies on the interactions between proteins and other molecules, including protein, 
DNA, RNA, lipids, carbohydrates, and small molecules. Among all the intermolecular 
interactions, protein-protein interaction (PPI) is the best-known mechanism that orchestrates 
proteins' cellular functions in several different ways (Phizicky and Fields, 1995, Rao et al., 
2014). 
 
First, PPI confers substrate specificity. For example, valosin-containing protein (VCP)/p97 is 
an ATPase that extracts ubiquitinated target proteins in diverse cellular processes. VCP  
interacts with mutually exclusive ubiquitin-binding cofactors that determine the substrate 
specificity (Buchberger et al., 2015, Meyer et al., 2012). Second, PPI serves as an allosteric 
switch for enzymatic activity. A scaffold protein, Ste5, binds the mitogen-activated protein 
kinase Fus3 and activates Fus3 autophosphorylation by 50-fold (Bhattacharyya et al., 2006). 
Third, via PPI, effector proteins read the molecular signals presented by associated proteins 
and translate the signals into downstream biological functions. Protein post-translational 
modifications (PTMs) are revolutionarily conserved signals that relay the molecular messages 
between various proteins responding to alterations in the cellular microenvironment (Deribe 
et al., 2010b). Deciphering the PPI networks between histone PTMs and their effector proteins 
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has become a central topic in the field of epigenetics (Jenuwein and Allis, 2001a). Various 
histone PTMs and corresponding effector protein families have been recently reviewed (Chen 
et al., 2019) and will be discussed in Chapter 3 of this dissertation. Lastly, PPI controls the 
formation and breakdown of subcellular structures. Monomeric actins polymerize into 
polarized filaments, termed F-actin, which makes up the cytoskeleton and drives cell motility 
(Olson and Sahai, 2009). 
 
1.1.2 Mass spectrometry-based detection method 
In the past few decades, genomic studies have identified many disease-associated gene 
mutations, but the underlying molecular mechanisms remain unknown. PPI plays an essential 
role for proteins to execute their functions. Therefore, identifying the pivotal PPI networks has 
proven to be a powerful approach to better understand the signaling transduction from histone 
codes to downstream pathways in healthy and pathological conditions. 
 
There are two primary experimental methodologies to map the PPI network, protein domain 
array-based approach (discussed in Chapter 3) and mass spectrometry (MS)-based 
approaches. The MS-based approach is an unbiased discovery method with superior 
sensitivity. There are three ways to capture the bait protein's PPI networks, affinity purification 
(AP), proximity labeling (PL), and cross-linking (XL), as reviewed recently (Richards et al., 
2021).  
 
AP-MS approach uses a tagged bait protein, enabling efficient purification without 
immunoprecipitation-compatible antibodies (Chang, 2006, Puig et al., 2001). The bait protein 
can be expressed exogenously in bacteria or endogenously via ectopic overexpression. The 
primary limitation is the necessity of mild lysis conditions, potentially missing those transient 




Complementary to AP-MS, the PL-MS approach utilizes a bait protein fused to a non-selective 
labeling enzyme, such as biotin ligase, which allows biotinylation of all nearby proteins within 
a 10-20 nm range (Gutierrez et al., 2016). Biotinylated proteins are then enriched via 
streptavidin binding, making this approach better suited for detecting transient or weak protein 
interactions. One critique for this method is the high background signals due to non-selective 
labeling of all proteins nearby (Lobingier et al., 2017).  
 
Both AP-MS and PL-MS approaches induce a tag/enzyme at the N- or C-terminus, which 
potentially affects the bait protein's PPI profiles and cellular functions (Sastry et al., 2009). In 
contrast, the XL-MS method freezes PPI networks via a chemical cross-linker such as 
formaldehyde, which reveals the structural information by linking the peptides near the binding 
interfaces without introducing artificial tags (Yu and Huang, 2018). This approach's primary 
limitation is that variously linked peptides pose a significant challenge to data analysis to 
consider all the possible combinations (Liu et al., 2015, Lu et al., 2018). 
 
All three MS-based approaches complement each other and are proven to be powerful tools 
to characterize novel PPI networks in an unbiased manner. 
 
1.2 OVERVIEW OF HISTONE H2A/H2B MONO-UBIQUITINATION 
1.2.1 Protein ubiquitination  
Ubiquitin is a 76-amino acid polypeptide. Ubiquitination is a process by which ubiquitin forms 
an isopeptide bond between its C-terminal glycine and a lysine residue from the target protein 
(Buetow and Huang, 2016, Komander and Rape, 2012). In addition, , Ubiquitin itself has seven 
lysine residues and an N-terminal methionine which can all be subjected to ubiquitination, 
enabling the formation of a variety of poly-ubiquitin branches/chains. A substrate can be post-
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translationally modified by mono-ubiquitin or polymeric ubiquitin chains. Komander and Rape 
first proposed the ubiquitin code hypothesis that different ubiquitin modifications harbor unique 
conformations that dictate various cellular outcomes (Komander and Rape, 2012). K48 linked 
poly-ubiquitin chains target the modified substrates for proteasomal degradation, while K63-
linked poly-ubiquitin chains and mono-ubiquitin regulate substrates’ localization or interaction 
with other proteins.  
 
All four core histones H2A, H2B, H3, and H4, and the linker histone H1 are heavily modified 
by mono- or poly-ubiquitination (Tweedie-Cullen et al., 2009). Among all the histone 
ubiquitination marks, mono-ubiquitination of histone H2A at K119 (H2Aub1) and H2B at K120 
(H2Bub1) are relatively well characterized.  H2Aub1 and H2Bub1 differ because of their 
unique sets of E3 ligases and deubiquitinases, distinct functions in gene transcription 
regulation, and DNA damage response. Notably, there are only two H2Aub1-specific effector 
proteins identified and no known H2Bub1-specific reader proteins (Zhang et al., 2017b, 
Cooper et al., 2016a).  
 
1.2.2 Histone H2A Mono-Ubiquitination at K119 
Writers and Erasers 
Ubiquitination of H2A at K119 is an abundant epigenetic mark, as 10% of all nucleosomal 
H2As have this modification (West and Bonner, 1980, Kalb et al., 2014c, Goldknopf et al., 
1975, Goldknopf and Busch, 1977). There are two major E3 ubiquitin ligases for H2Aub1, the 
really interesting new gene 1A/1B (RING1A/RING1B) from the polycomb repressive complex 
(PRC1) and the DAZ Interacting Zinc Finger Protein 3 (DZIP3) along with the N-CoR/HDAC1/3 
complex  (Li et al., 2006, Gray et al., 2016, Kalb et al., 2014c, Zhou et al., 2008). There are 
two major H2Aub1 DUBs, USP16 and breast cancer type 1 susceptibility protein (BRCA1)-





The remodeling and spacing factor (RSF1) is a H2Aub1-specific reader protein.  ChIP-Seq 
analyses show overlapping binding profiles of RSF1, H2Aub1, and RING1B. RSF1 knockout 
caused H2Aub1 chromatin organization changes and transcriptional upregulation of H2Aub1-
associated genes, indicating RSF1 facilitates H2Aub1-mediated gene silencing by 
maintaining a stable nucleosome pattern at promoter regions (Zhang et al., 2017b).  
 
The other H2Aub1-specific effector protein is Jarid2, a PRC2 cofactor that was first identified 
in Drosophila using an AP-MS approach (Cooper et al., 2016a). Jarid2 is required for PRC2 
complex recruitment to the H2Aub1-modified chromatin and PRC2-mediated H3K27me3 
mark (Kalb et al., 2014b, Cooper et al., 2016b). This discovery provided a mechanistic 
rationale for the positive-feedback-loop model between two repressive histone marks, 
H2Aub1, and H3K27me3, deposited by PRC1 and PCR2, respectively. 
 
Functional characterization 
Enriched at the promoters of target genes, the H2Aub1 functions as a transcriptional repressor 
that blocks transcription elongation by preventing FACT complex recruitment and recruiting 
PRC2 complex. The latter deposits the repressive H3K27me3 mark. H2Aub1 also recruits the 
RSF1 complex that maintains repressive chromatin conformation (Zhou et al., 2008, Cooper 
et al., 2016a, Kalb et al., 2014a, Cooper et al., 2014).  
 
H2Aub1 is involved in DNA damage repair through its ability to repress local transcription at 
the regions flanking damage sites and also promotes homologous recombination 




1.2.3. Histone H2B Mono-Ubiquitination at K120 
Writers and Erasers  
Ubiquitination of histone H2B at K120 is present on 1% of all nucleosomal H2Bs (West and 
Bonner, 1980). RNF20/RNF40 complex is the major E3 ubiquitin ligase for H2Ub1, while 
MDM2 and BAF250/ARID1 also display H2Bub1-specific E3 ligase activity (Zhu et al., 2005, 
Kim et al., 2009, Minsky and Oren, 2004, Li et al., 2010). There are nine H2Bub1-targeting 
DUBs in human cells, USP3, USP22, USP27X, USP36, USP42, USP43, USP44, USP49, and 
USP51 (Nicassio et al., 2007, Zhang et al., 2008, Zhang et al., 2013, Hock et al., 2014, Gu et 
al., 2016, Lan et al., 2016, DeVine et al., 2018, He et al., 2018, Zhao et al., 2008, Atanassov 
et al., 2016). As the DUB module of the SAGA complex, USP22 is the best-characterized DUB 
for H2Bub1. Additionally, USP22, USP27X, and USP51 function in distinct pathways, but they 
compete for the same cofactors, ATXN7L3 and ENY2, to be enzymatically activated 
(Atanassov et al., 2016). This finding suggests a regulatory mechanism that balances the 
activities of different DUBs by limiting the availability of their shared adaptor proteins.   
 
Readers 
To date, there are no known H2Bub1-specific effector modules.   
 
Functional characterization 
H2Bub1 drives transcriptional activation by maintaining an open chromatin conformation, 
facilitating transcription elongation by RNA polymerase II together with FACT complex, 
promote active transcription marks, H3K4me2/me3 and H3K79me1/me2 by Set1 and DOT1L, 
respectively (Shiloh et al., 2011, Fierz et al., 2011, Pavri et al., 2006, Kim et al., 2009). 
However, the H2Bub1-specific effectors that mediate the crosstalk between H2Bub1 and 




H2Bub1 is required for efficient DNA damage repair by non-homologous end-joining (NHEJ) 
and homologous recombination (HR) repair pathways (Nakamura et al., 2011, Moyal et al., 
2011). Besides, antibody class-switch recombination repair requires the removal of H2Bub1 
by the SAGA complex, as H2Bub1 inhibits ATM- and DNAPK-induced γH2AX formation 
(Ramachandran et al., 2016, Li et al., 2018). However, H2Bub1-specific effectors for all the 
above functions are still yet to be determined. 
 
1.3 PLAA IN UBIQUITIN MAINTENANCE 
1.3.1 Doa1 to PLAA: Evolutionary Conservation From Yeast to Human 
Melittin, a bee venom peptide, is a phospholipase A2 (PLA2) stimulatory peptide. In search of 
the mammalian PLA2 stimulator, Clark et al. first purified a mammalian protein using anti-
melittin antibodies. They thus named the protein phospholipase A2 activating protein (PLAA) 
(Clark et al., 1988, Clark et al., 1987). They also found that melittin displays a high degree of 
sequence homology with PLAA between residues 503-538 (Bomalaski et al., 1990, Clark et 
al., 1991). Inflammatory mediators, including LPS, IL-1β, and TNFα, stimulated PLAA protein 
expression levels and increased PLA2 activity and prostaglandins (PGE2) levels. PGE2 was 
produced from arachidonic acid (AA) that was hydrolyzed from phospholipids by PLA2. 
Treatment with PLAA-specific antisense oligonucleotide caused reduced PLA2 levels 
(Ribardo et al., 2001). However, the molecular mechanism by which PLAA regulates PLA2 
remains elusive. 
 
PLAA’s yeast ortholog, Doa1, also known as Ufd3, was first discovered as a critical player in 
the ubiquitin fusion degradation (UFD) pathway, together with Ufd1, Ufd2, Ufd4, and Ufd5 
(Johnson et al., 1995). Both Doa1 and PLAA consist of an N-terminal WD40 domain, a central 




WD40 domain is a UBD and required for Doa1’s functions 
Pashkova et al. solved the crystal structure of the Doa1 WD40 (residues 1-300) domain with 
ubiquitin. The WD40 repeat β-propeller binds to mono-ubiquitin with a Kd of 220 uM, 
determined by chemical shift perturbation. Mutations of residues on the interaction surface 
disrupted ubiquitin binding and caused growth defects in yeast. Surprisingly, mutations in both 
WD40 and PFU domains caused synthetic growth defects (Pashkova et al., 2010). 
 
PFU domain is a novel ubiquitin-binding module 
Wilkinson and colleagues first identified Doa1 as a novel K29-linked polyubiquitin binding 
protein and mapped the minimal UBD residing between residue 350 and 450. They named 
this domain the PLAA family ubiquitin-binding (PFU) domain, as this region displays high 
sequence homology between Doa1 and PLAA (Mullally et al., 2006, Russell and Wilkinson, 
2004). Furthermore, a Doa1-PLAA chimera protein, consisting of the Doa1 WD40 domain and 
PLAA PFU and PUL domains, complemented the ubiquitin depletion phenotypes and growth 
defects observed in Doa1-null yeast, suggesting an evolutionarily conserved function of PFU 
and PUL domains (Mullally et al., 2006). 
 
The PFU domain of human PLAA is a relatively weak mono-ubiquitin binder with a Kd of 1 
mM, determined by chemical shift perturbation (Fu et al., 2009a).   
 
PUL domain interacts with Cdc48 
PUL domain contains six Armadillo-repeats. Several groups demonstrated that the Doa1 PUL 
domain interacts with Cdc48 (Decottignies et al., 2004, Ghislain et al., 1996, Ogiso et al., 2004, 
Mullally et al., 2006).  Structural studies showed Doa1 PUL domain binds the Cdc48 C-
terminus with a Kd of 3.5 uM, determined by isothermal titration calorimetry. The PUL domain 
mutations that disrupt the interaction with Cdc48 caused the depletion of the cellular ubiquitin 
 
 9 
and disruption of protein degradation, suggesting that Doa1-Cdc48 interaction is required to 
maintain ubiquitin homeostasis (Zhao et al., 2009). 
 
1.3.2 Functional Characterization of PLAA/Doa1 
PLAA/Doa1 is involved in four distinct pathways, ubiquitin homeostasis, DNA damage repair, 
lysosome damage response and mitochondrial membrane protein quality control (Johnson et 
al., 1995, Lis and Romesberg, 2006, Papadopoulos et al., 2017, Wu et al., 2016). 
 
Apart from other UFD regulators (Ufd1, Ufd2, Ufd4, and Ufd5), only Doa1-null mutant showed 
an abnormally low content of free ubiquitin and defective degradation of Ub-P-βgal (Johnson 
et al., 1995). Ub-P-βgal is a model protein that is targeted and degraded by the ubiquitin fusion 
degradation pathway (Johnson et al., 1992). Notably, overexpression of ubiquitin rescued the 
defective degradation of Ub-P-βgal in Doa1-null cells, indicating Doa1 regulates degradation 
of Ub-P-βgal indirectly by controlling the availability of free ubiquitin. 
 
Doa1 regulates the concentration of free ubiquitin partially by processing K48-linked 
polyubiquitin trimers (K48-UB3). Lis et al. found that reduced free mono-ubiquitin coincided 
with the accumulation of K48-UB3 but not K63-Ub3 in Doa1-null cells (Lis and Romesberg, 
2006). The affinity purified Doa1 complex displayed deubiquitinase activity towards K48-linked 
tri-ubiquitin in vitro. However, it was unknown whether Doa1 itself or its associated protein(s) 
had the K48-Ub3 specific deubiquitinase activity. This study only tested K48-Ub3 and K63-
Ub3, and it remained unknown whether Doa1 can hydrolyze other types of polyubiquitin, such 





Doa1 is a DNA damage "responder" by making ubiquitin available for pathways that regulate 
DNA replication machinery and histone H2B ubiquitination (Lis and Romesberg, 2006). Doa1-
null cells displayed reduced H2Bub1. Moreover, Doa1 depletion abolished DNA damage-
induced PCNA ubiquitination and H2Bub1. Interestingly, overexpression of ubiquitin only 
reversed the defective PCNA ubiquitination but not the H2Bub1 in Doa1-null cells, suggesting 
Doa1 modulates H2Bub1 via a mechanism beyond merely providing ubiquitin. This study 
solely focused on H2Bub1, and it was unknown how Doa1 depletion affected other histone 
ubiquitination marks. This result specifically interested me because I have found that PLAA is 
required for maintaining H2Bub1 levels in mammalian cells in Chapter 4. 
 
Doa1 also functions as a ubiquitin receptor for the mitochondrial-associated degradation 
(MAD) pathway and it forms a complex together with Cdc48, Ufd1, and Npl4 (Wu et al., 2016). 
Doa1 facilitates complex recruitment by interacting with ubiquitinated proteins on the 
mitochondrial outer-membranes. Doa1 has two UBDs, WD40 and PFU domains. Mutations of 
the critical residues in WD40 and PFU domains repressed the turnover of different subsets of 
substrates, suggesting that these two UBDs have unique binding characteristics towards 
ubiquitinated substrates, the mechanisms of which have yet to be determined. 
 
PLAA is involved in the clearance of damaged lysosomes by forming the endo-lysosomal 
damage response (ELDR) complex together with VCP/p97, YOD1, and UBXD1 
(Papadopoulos et al., 2017). Upon localization to the ruptured lysosomes, the ELDR complex 
selectively removes K48-Ub conjugates but not K63-Ub conjugates. Depleting of PLAA and 
other two co-factors by siRNA led to the accumulation of lysosomes decorated by K48-Ub 
conjugates. This was consistent with another study done in yeast that discovered purified 




Ubiquitin binding activity is necessary for Doa1's functions. 
Depletion of Doa1 leads to decreased mono- and polyubiquitin, suggesting Doa1 is involved 
in ubiquitin homeostasis maintenance. Doa1-null yeast also displays increased sensitivity to 
protein misfolding and translation inhibition (Mullally et al., 2006). Notably, the Ub binding-
deficient Doa1 mutant (F417D and F434D) only partially rescued the Doa1-null phenotypes, 
compared to wildtype Doa1, suggesting a functional Doa1 requires its ubiquitin-binding activity. 
 
1.3.3 Implication of PLAA in Neurological Dysfunction  
Homozygous mutations in PLAA cause severe neurological disorders in humans (Falik Zaccai 
et al., 2016, Hall et al., 2017). Zaccai et al. reported that PLAA L752F mutation causes 
progressive microcephaly and leukoencephalopathy in patients at ages 2 to 4 months (Falik 
Zaccai et al., 2016). They discovered that this homozygous mutation abolishes PLAA's 
function to induce PLA2 activity. As a result, the production of prostaglandin E2 (PGE2), a 
process catalyzed by PLA2, was also decreased. PLAA-null mice were perinatal lethal with 
reduced levels of PGE2 in the brain and lung of PLAA-null embryos. These results provided 
evidence that inefficient PGE2 signaling underlies the developmental defect caused by a non-
functional PLAA. 
 
Hall et al. discovered another hypomorphic PLAA mutation, G23V, that also causes severe 
developmental delay and seizures in affected infants (Hall et al., 2017). They found the G23V 
mutation impairs PLAA's function in the ubiquitin-mediated trafficking of membrane proteins 
for lysosomal degradation, causing reduced synaptic vesicle numbers and altered 
neurotransmission. PLAA-null embryos also died in mid-gestation while PLAA G23V/G23V 
are viable. The G23V mutation destabilized PLAA, with the mutant protein's abundance at 
only 30% of the wild-type counterpart. These results elucidated PLAA's role in regulating 
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membrane components' turnover in both central and peripheral synapses, which provided 
mechanistic insights on PLAA G23V mutation-caused neurological dysfunction. 
 
1.4 HISTONE H3K4 RECOGNITION MODULES 
Serving as a central hub and carrying a variety of histone PTMs, histone N-terminal tails 
orchestrate the recruitment of protein complexes that change the chromatin landscape at the 
target gene loci (Jenuwein and Allis, 2001a, Kouzarides, 2007, Ruthenburg et al., 2007b, 
Taverna et al., 2007, Strahl and Allis, 2000a). A combination of different PTMs on histone tails, 
including methylation, acetylation, and phosphorylation, has been termed the “histone code” 
(Jenuwein and Allis, 2001a). Single or combinatorial histone codes dictate the formation of 
specific chromatin-associated protein complexes that are involved in chromatin remodeling 
and transcriptional regulation. As an active transcription mark, histone H3K4me3 is found at 
the transcription start site (TSS) of almost every active gene (Bernstein et al., 2005, Ng et al., 
2003, Pokholok et al., 2005, Santos-Rosa et al., 2002, Schneider et al., 2004, Schübeler et 
al., 2004). Transcriptional initiation encoded by H3K4me3 is accomplished by the direct 
recruitment of reader modules from the transcription machinery and chromatin remodeling 
complex (Vermeulen et al., 2007, Wysocka et al., 2006). There are two major H3K4me3 
reader families: the royal superfamily (chromodomains of CHD1 and Tudor domains of 
JMJD2A), and the PHD-finger superfamily (Sims et al., 2005, Flanagan et al., 2005, Maurer-
Stroh et al., 2003, Bienz, 2006, Huang et al., 2006a). This study is focused on the PHD-finger 





1.4.1 PHD Domain Superfamily Proteins 
PHD fingers are characterized by a conserved zinc-coordinating Cys4-His-Cys3 motif 
(Aasland et al., 1995). On one hand, PHD fingers exhibit high sequence variability, providing 
various binding specificity towards H3K4me0 and K3K4me2/3 as the two major PHD ligand 
classes (Fiedler et al., 2008, Ramón-Maiques et al., 2007, van Ingen et al., 2008, Hung et al., 
2009, Taverna et al., 2006, Wang et al., 2009a, Frottin et al., 2006, Wen et al., 2010, Ooi et 
al., 2007, Org et al., 2008, Chakravarty et al., 2009, Lan et al., 2007) and towards H3R2me0, 
H3R2me2, and H3K14ac as minor ligands (Zeng et al., 2010, Chignola et al., 2009). On the 
other hand, PHD fingers share two adjacent ligand-binding surfaces that stabilize the 
positively charged side chains of R2 and K4. These two residues determine whether the H3 
N-terminal R2-T3-K4 motif can interact with PHD fingers (Ruthenburg et al., 2007a). A clear 
example of this can be observed in BPTF (PHD), whose R2 is anchored in place by hydrogen 
bonds and electrostatic interactions with negatively charged D27 while its K4me3 is stabilized 
by van der Waals and cation-p interactions within an aromatic cage. Notably, the free N-
terminal amine forms a pair of hydrogen bonds with adjacent backbone carbonyls, enhancing 
the binding specificity of BPTF-H3K4me3 (Wysocka et al., 2006, Ruthenburg et al., 2011). 
The free N-terminus of histone H3 is generated by enzymes that facilitate the cleavage of the 
initial methionine (iMet) (Brandt et al., 1974, Song et al., 2003). 
 
1.4.2 Initiator Methionine Cleavage 
Initiator methionine cleavage is a co-translational process that is mediated by the methionine 
aminopeptidase (MAP). There are two MAPs in yeast and humans, MAP1 and MAP2 
(Giglione et al., 2004, Bradshaw et al., 1998). Around two-thirds of proteins in the human 
proteome undergo initial methionine cleavage. The specificity of this process is determined 
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by the size of the P1’ residue, which is the amino acid that is adjacent to the iMet (Frottin et 
al., 2006, Sherman et al., 1985, Wingfield, 2017b). The initiator methionine is usually cleaved 
when the P1’ residues have side chains with a gyradius of 1.29 Angstroms (Å) or less. Seven 
amino acids are permissible for iMet cleavage: glycine, alanine, serine, threonine, cysteine, 
proline, and valine. Histone H3 has alanine (A1) at the P1’ position; therefore, its iMet can be 
cleaved, generating a free N-terminus that stabilizes the H3-PHD finger interactions 
(Ruthenburg et al., 2011, Wysocka et al., 2006, Frottin et al., 2006).  
 
1.5 HISTONE MIMICRY  
Non-histone proteins with a histone-like sequence motif are called histone mimics. These 
proteins have the ability to mimic the H3 amino tail’s interaction with modification-specific 
recognition modules (Marazzi et al., 2012, Sampath et al., 2007). One example of these 
mimics is the histone H3 methyltransferase G9a, which carries a 163ARKT166 motif that is 
similar to the 7ARKS10 motif of histone H3. Similar to H3K9, the K165 residue can be 
methylated by G9a, and G9a K165me2/3 interacts with the H3K9me2/3 effector HP1 
(Bannister et al., 2001, Sampath et al., 2007).  
 
Another example is the nonstructural protein 1 (NS1) of the influenza A virus H3N2 subtype. 
NS1 has a C-terminal 226ARSK229 motif that resembles the N-terminal 1ARTK4 motif of histone 
H3. This C-terminal motif interacts with the human PAF1 transcription elongation complex 
(hPAF1c), suppressing antiviral gene expression by blocking hPAF1c-mediated transcription 
elongation (Marazzi et al., 2012). NS1 K229me2, like dimethylated H3K4, interacts with the 
double chromodomains of chromatin remodeler, CHD1 (Qin et al., 2014).  In addition, we have 
identified an internal H3-like 173ARTK176 motif in PRMT6 that can be automethylated at the R 
residue (not shown). Notably, the ART/SK motifs of both NS1 and G9a are located at the C-
terminal regions rather than N-terminal regions like histone H3, which suggests methylation 
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of the H3-mimicking motifs are critical, and location of the motifs, to a lesser extent, for 
hijacking  chromodomains (Qin et al., 2014, Sampath et al., 2007). This also aligns with 
characterization of chromodomains as specialized methyl-lysine reader domains (Yap and 
Zhou, 2011).  
 
In contrast, PHD fingers, the H3 N-terminal methyl-lysine reader families, have no known non-
histone ligands identified. We started the project by asking whether there are proteins in the 
human proteome that have an H3-like N-terminal motif and whether they can interact with 
known H3K4me3-reader proteins in a methylation-dependent manner, which could 
dramatically expand the PHD interaction network.  
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CHAPTER 2: MATERIALS AND METHODS 
Development of ubiquitin-binding domain and methyl reader domain microarrays: 
Protein domain microarray generation and probing have been published (Espejo and Bedford, 
2004a). There are 150 ubiquitin-binding domains and 225 methyl reader domains on the two 
microarray chips, respectively (Table 1 and Table 2).  
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9 6 M 7 10
7 8 11 3 5
1 5 9 4 8
A B C
D E F G
L M N
H J KI
Table 1. Ubiquitin inding Domain A rays
 
 17 




Probe Design and Synthesis: Ubiquitination and methylation (and unmodified form) probes 
were synthesized and purified by LifeSensors and CPC Scientif Inc., respectively (Table 3). 
The peptides, received in powder form, were dissolved in milli-Q water and stored at -20 °C. 
 
Table 3: Peptide probes used in this dissertation 
Protein (location) Probe Sequence Information Vendor 
Histone H2A (112-129) Biotin-Ahx-QAVLLPKK(Ub)TESHHKAKGK LifeSensors 
Histone H2B (113-125) Biotin-Ahx-EGTKAVTK(Ub)YTSSK LifeSensors 
VRK1 (2-13) PRVK(me3)AAQAGRQS-Biotin CPC Scientific Inc. 
BCL11B (2-13) SRRK(me3)QGNPQHLS-Biotin CPC Scientific Inc. 
TSHZ1 (2-13) PRRK(me3)QQAPRRSA-Biotin CPC Scientific Inc. 
HIVEP1 (2-13) PRTK(me3)QIHPRNLR-Biotin CPC Scientific Inc. 
PCLAF (2-13) VRTK(me3)ADSVPGTY-Biotin CPC Scientific Inc. 
MAPK8(2-13) SRSK(me3)RDNNFYSV-Biotin CPC Scientific Inc. 
MEF2C(2-13) GRKK(me3)IQITRIMD-Biotin CPC Scientific Inc. 
HIRIP3(2-13) AREK(me3)EMQEFTRS-Biotin CPC Scientific Inc. 
Histone H3 (2-19): ARTK(me3)QTARKSTGGKAPRK-Biotin CPC Scientific Inc. 
 
Peptide pull-down assays: Biotinylated peptides (6 µg) were immobilized on 25 ul of 
streptavidin beads (Sigma, St Lous, MO, USA) in 500 µL of binding buffer (50 mM Tris-HCL 
pH 7.5, 150 mM NaCl, 1mM EDTA, 1mM EGTA, 0.5 % NP-40) at 4 °C for 1 hr. The beads 
were washed with binding buffer three times and incubated with 10 µg of glutathione S-
transferase (GST) fusion protein or 30 ug 293T cell lysates for 1 hr with rotation at 4 °C. After 
three washes with binding buffer, the beads were boiled in 2X protein loading buffer and 
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subjected to SDS-PAGE followed by western blot analyses. Western blot analysis was 
performed as described previously (Kim et al., 2006a). 
 
Nucleosomal pull-down assays: Three recombinant nucleosomes, unmodified dNuc, 
H2AK119ub dNuc, and H2BK120ub dNuc, were generously provided by Dr. Zu-Wen Sun from 
EpiCypher (Durham, NC). Mono-nucleosomes were assembled from recombinant human 
histones expressed in E. coli and wrapped by the 601 positioning sequence linked with a 5’ 
biotin-TEG group (Lowary and Widom, 1998). Nucleosomal binding assays were performed 
under the same conditions as the peptide pull-down assays. 
 
Antibodies: For western blots: anti-PLAA (Santa Cruz, 1:1000), anti-PLAA (Proteintech, 
1:1000), anti-GFP (Santa Cruz, 1:1000), anti-H2B K120ub1 (Cell Signaling, 1:2000), anti-H2A 
K120ub1 (Cell Signaling, 1:2000), anti-H3 (Abcam, 1:5000), anti-flag (Sigma-Aldrich,1;5000), 
anti-VCP (Cell Signaling, 1:2000), anti-PHF2 (Cell Signaling, 1:2000), anti-MTA1 (Cell 
Signaling, 1:2000), anti-ING2 (Proteintech, 1:1000), anti-SPIN1 (ThermoFisher Scientific, 
1:2000), and anti-GST (Covance, 1:5000), HRP-conjugated streptavidin antibody 
(ThermoFisher Scientific, 1:5000)  
 
For immunofluorescence (IF): anti-γH2AX (Millipore, 1:200), anti-PLAA (Proteintech, 1:200), 
anti-H2B K120ub1 (Cell Signaling, 1:200), F-actin (Sigma-Aldrich, 1:5000), Alexa Fluor 488 
goat anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse IgG, Alexa Fluor 594 goat anti-rabbit 
IgG, and Alexa Fluor 594 goat anti-mouse IgG (ThermoFisher Scientific, 1:500) 
 
Cell culture: MCF-7, 293T, Hela, Huh-7, Hep-G2 and Hep-3B cell lines were tested to be 
mycoplasma free using the MycoAlertTM kit (Lonza) and were cultured in DMEM (Gibco, 
12100046) supplemented with 10% fetal bovine serum (Gibco, heat-inactivated), MEM non-
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essential amino acids (Gibco, 11140050) and penicillin-streptomycin (Gibco, 50 U/mL, final 
concentration) 
 
CRISPR/Cas9 plasmid construction and lentiviral packaging: 5 µg of the lentiCRISPRv2 
plasmid was digested with 3 µL BsmBI (NEB, R0739) in 60 µL 1X NEBufferTM 3.1 (NEB) for 1 
hour at 55 °C and the 11 kb backbone fragment was purified by 0.8% agarose gel 
electrophoresis and PCR & DNA Cleanup Kit (Monarch, T1030L).  
 
A single guide RNA (sgRNA) targeting the Exon 1 of PLAA was designed using the Broad 
Institute GPP (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). 
Oligos, synthesized by Integrated DNA Technologies (IDT), were phosphorylated using the 
T4 PNK (NEB M0201S) in 10 µL T4 ligase buffer (NEB). The product was first denatured at 
95 °C for 5 min, then slowly annealed to 25°C at 5 °C/min.  
The annealed oligos and the 11 kb backbone were ligated using the Quick Ligase (NEM 
M2200S) and transformed into Stbl3 competent cells. Plasmids were then sequenced to 
ensure the oligos were cloned into the backbone correctly. 
 
Production of lentivirus was performed in 293T cells by co-transfection of pVSVg (Addgene 
#8454) and psPAX2 (Addgene, #12260) and the lentiviral plasmid using Lipofectamine 2000 
(Invitrogen), as described (Sanjana et al., 2014, Shalem et al., 2014). The cell culture medium 
was collected 48 hours after transfection, filtered through a 0.22 µM membrane and 




The MCF-7 cell line was infected with the lentivirus. Puromycin (1 µg/ml) was added to the 
culture medium 48 hours after the infection. The cells were plated at a low density to get well 
separated colonies. Single cell clones were manually picked and expanded for validation.  
 
Table 4: Primers used in this dissertation 
Primer Sequence (5’ to 3’) 
PLAA Exon1-targeting sgRNA (F) CACCGGGCCACGAGCTGGACGTACG 
PLAA Exon1-targeting sgRNA (R) AAACCGTACGTCCAGCTCGTGGCCC 
PLAA KO Sequencing Primer (F) GCTGAGGCCGATGATGAAT 
PLAA KO Sequencing Primer (R) GACTCGTCTGTGGTCAAGTTAG 
PLAA WD40 N-term (F) TAAGTCGACATGACGAGCGGCGCAACC 
PLAA PFU N-term (F) TTAGCTCGAGCTCCTGGTACTAGAGAAGGA 
PLAA PFU C-term (R) ATAGGATCCACTACTACCACTAGAACCCGG 
PLAA PUL C-term (R) GCCCGCGGCTACAGCAAATTTAGGATAAA 
VRK1 K4A (F) GCCTCGTGTAGCAGCAGCTCAAG 
VRK1 K4A (R) ATGGTGGCCTCGAGATCT 
VRK1 TEV (F) TTTTCAGGGCAGCTCTGCAAAGAGACATC 
VRK1 TEV (R) TACAGGTTTTCCTGTCTTCCAGCTTGAGC 
BCL11B K4A (F) GTCCCGCCGCGCACAGGGCAAC 
BCL11B K4A (R) GTCCCGCCGCGCACAGGGCAAC 
TSHZ1 K4A (F) GCCGAGGAGGGCGCAGCAGGCC 
TSHZ1 K4A (R) GCCGAGGAGGGCGCAGCAGGCC 
MEF2C K4A (F) GGGGAGAAAAGCGATTCAGATTACGAGGATTATG 
MEF2C K4A (R) GGGGAGAAAAGCGATTCAGATTACGAGGATTATG 




Plasmid construction: Human codon-optimized plasmids, GFP-PLAA, GFP-ANKIB1, VRK1-
GFP, BCL11B-GFP, MEF2C-GFP, TSHZ1-GFP, PCLAF-GFP, MAPK8-GFP were 
synthesized by Biomatik (Ontario, Canada). Construction of GFP-tagged PLAA truncations 
were done by polymerase chain reaction (PCR) using GFP-PLAA as a template. PCR uses a 
combination of specific primers that are added to the template DNA to amplify genes in a 
specific way (See Table 4 for primer sequences). 
 
In vitro methylation assay: The GST-Set7/9 was expressed and purified as described 
previously (Cheng et al., 2007). The recombinant MLL1 and PRDM9 proteins were purchased 
from Reaction Biology Corp (Malvern, PA) and Active Motif (Carlsbad, CA), respectively. In 
vitro methylation reactions were performed in a final volume of 30 µl of 50 mM Tris-HCl (pH 
8.5), 5 mM MgCl2, 4mM DTT, and 0.42 µM 3H-labeled S-adenosyl-L- [methyl 3H] methionine 
(PerkinElmer Life Sciences) (Nishioka et al., 2002, Hamidi et al., 2018). 
 
Live cell microirradiation imaging and immunofluorescence microscopy  
Laser microirradiation imaging: Laser microirradiation and quantification of live-cell imaging of 
laser damage recruitment were performed with Zeiss Zen software on a Zeiss LSM 880 
confocal microscope (Zeiss) following standard protocols designed in previous studies (Gong 
et al., 2015). In brief, cells were seeded onto (World Precision Instruments, FD35-100) and 
co-transfected using PEI with 2 µg GFP-PLAA plasmid and 2µg RFP-53BP1. Media was 
changed 4~6 hours after transfected cells and cells were cultured for another 24 hours. All 
cells used for laser microirradiation and after the experiments (live-cell imaging and 
immunofluorescence) were pre-sensitized by adding 10 μM BrdU in regular DMEM medium 
for 20 hr or with 200ng/mL Hoechst33342 (Thermo Scientific, Cat# 62249) for 30 mins before 
damage treatment. Live-cell imaging experiments were performed at 37°C and 5% CO2 
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conditions maintained by a heated incubation system on the microscope. All images were 
captured using a Zeiss 40X water objective lens. A 355-nm laser beam (30%) was used to 
generate laser microirradiation. For each experiment, quantification data were collected 
from >10 cells under each condition. Plots shown in figures are from one representative 
experiment. 
 
Immunofluorescence: After indicated treatments, cells were rinsed with 1X PBS and then 
fixed/permeabilized with 100% Methanol at -20 °C for 10 mins (as required by H2Bub1 
antibody) or fixed with 4% formaldehyde for 10 min at room temperature for all other 
antibodies. Upon fixation, cells were blocked with PBS containing 3% BSA. After blocking, 
cells were incubated with indicated primary antibodies and corresponding secondary 
antibodies. Finally, the cells were stained with DAPI at room temperature. Confocal images 
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3.1 CELL SIGNALING THROUGH POSTTRANSLATIONAL MODIFICATIONS 
PTM is the process of covalently adding a chemical group to an amino acid in a protein after 
the protein has been synthesized. PTMs are usually enzymatically added to and removed 
from the protein substrates. The most prominent types of PTMs are phosphorylation, 
methylation, acetylation, glycosylation and ubiquitination, but this is by no means a complete 
list (Deribe et al., 2010a). It has long been known that PTM patterns are altered in response 
to extracellular signals like growth stimulation and intracellular signals like DNA damage. Thus, 
activated and altered signaling cascades drive information from the cell surface to the nucleus, 
and also from the nucleus to the cytoplasm. These transduction processes are critical for cells 
within organisms to respond to information in their environment, and often culminate in 
epigenetic changes and altered gene expression signatures (Badeaux and Shi, 2013). These 
signals are transduced or relayed by effector proteins that often read one type of PTM and 
deposit a different type of PTM, thus the term “signal transduction cascade”.  
 
3.2 PROTEIN DOMAINS: INTERACTION HUBS THAT DRIVE SIGNALING CASCADES 
The concept that distinct protein regions within a continuous peptide chain can form globular 
structures was originally proposed by Donald Wetlaufer (Wetlaufer, 1973). This notion of 
globular protein domains was expanded to include both structure and function (Richardson, 
1981). Domains are the smallest functional and structural unit of a protein and are usually 
between 30 to 100 amino acids in length. Protein domains are not only regions that are 
expected to be stable as independent units, but they are also often conserved regions 
between different proteins. Thus, different proteins can be grouped into a family if they share 
the same domain, as the shared domain often confers similar functions. Protein domain 
identification has been greatly improved with advances in bioinformatics techniques. This 
provides the premise to predict novel domains/functions of a protein based on both sequence 
and structural information. The discovery by the Pawson group in the mid 90s, that SH2 
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domains are the modular units that engage phospho-tyrosine motifs (Songyang et al., 1993), 
set the stage for the discovery of a large number of domain types that “read” different PTMs, 
unique motif folds (like proline-rich sequences), phospholipids, metabolites and modified 
nucleic acids (Figure 1 & Table 5).  Therefore, domains can be considered the structural 
“hubs” within proteins that drive interactions, and facilitate the formation of regulatable protein 























Figure 1. Distinct domains, depicted with different colors and shapes are able to 
recognize specific motifs. Some domains recognize motifs that harbor PTMs, while others 
recognize distinct proline-rich sequences, nucleic acids or phospho-lipids. Y, tyrosine; S, 
serine, T, threonine; K, lysine; P, proline; ɸ-COOH, hydrophobic C-terminal; p, 





 Table 5. List of major protein domains that participate in signal transduction 
SH2 Src Homology 2 
PTB Phosphotyrosine-binding domain 
FHA Forkhead-associated domain 
14-3-3 The 14th elution fraction of DEAE-cellulose chromatography and the migration 
position 3.3 of subsequent electrophoresis 
BRCT BRCA1 C Terminus domain 
PBD Polo-box domain 
WW Containing two conserved Tryptophans that are 20-22 amino acids apart 
Tudor Named after the Tudors family for grandchildless phenotype 
Chromo chromatin organization modifier domain 
MBT Malignant brain tumor domain 
PHD Plant homeodomain 
BAH Bromo-adjacent homology 
ANK Ankyrin repeats domain 
PWWP Presence of a central core region 'Pro-Trp-Trp-Pro' 
WD40 A 40 amino acid motif with a terminating ‘Trp-Asp’ dipeptide 
Bromo Identified as a novel structural motif when studying the drosophila gene Brahma 
(brm) 
YEATS Yaf9, ENL, AF9, Taf14, Sas5 domain 
UBA Ubiquitin-associated domain 
UBX An 80 amino acid module with unknown function found in ubiquitin-
related/unrelated proteins 
UIM Ubiquitin-interacting motif domain 
VHS Originally found in VPS-27, Hrs and STAM proteins 
CUE A homology region between yeast Cue1 and human Tollips proteins 
PFU PLAA family ubiquitin-binding domain 
GAT A homology region in eukaryotic GGAs and vertebrate TOMs proteins 
ZZ ZZ-type zinc finger (ZZ) 
PTB Phosphotyrosine-binding domains 
SH3 Src Homology 3 
EVH1 WH1, RanBP1-WASP, or enabled/VASP homology 1 domain 
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3.3 EARLY DEVELOPMENT OF PROTEIN MICROARRAYS  
Some of the earliest protein screening approaches employed phage expression libraries to 
identify novel protein-protein interactions (Cicchetti et al., 1992, Chan et al., 1996) and 
discover kinase substrates (Fukunaga and Hunter, 1997). High-density arrays using 
bacterially produced His-tagged proteins were also developed at about the same time, and 
were used for protein ligand screening (Bussow et al., 1998) and enzyme substrate screening 
(Lee and Bedford, 2002). The disadvantage of both approaches was that the recombinant 
proteins were arrayed on large membranes, and not microarrayed on slides, which made 
certain assays difficult, because enzymatic reactions or protein interaction probing 
experiments need to be performed in very large volumes (30-50 ml). This issue spawned the 
development of microarrays that could be used for miniaturized high-throughput screening, 
in which proteins were spotted onto chemically derivatized glass slides at high density 
(MacBeath and Schreiber, 2000, Zhu et al., 2001). More recently, large-scale protein domain 
microarrays have become broadly available, and represent the commercialization of 
pioneering work from Snydner’s group at Stanford University (Smith et al., 2005) and the Zhu 
and Blackshaw laboratories at Johns Hopkins University (Jeong et al., 2012, Lu et al., 2013). 
The ProtoArrayTM is offered by Thermo Fisher Scientific and contains over 9,000 proteins on 
a single slide. These human proteins are expressed in insect cells as N-terminal GST-tagged 
fusions and printed onto nitrocellulose coated glass slides. The second commercially 
available human proteome microarray is called HuProtTM and is available from CDI. This 
microarray harbors over 16,000 proteins, which are also N-terminal GST-tagged fusions, but 
in this case, the recombinant proteins are expressed in yeast cells and then printed directly 
onto glass slides. A third type of protein array was generated by spotting protein-coding 
plasmids onto slides, and then translating these coding regions into proteins using a cell free 
reticulocyte lysate (He and Taussig, 2001, Ramachandran et al., 2004). These proteins are 
fused to a tag that allows immediate immobilization in situ, and they are called nucleic acid 
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programmable protein arrays (NAPPAs). Human NAPPA arrays with over 11,000 proteins are 
available through the Protein Array Core of the BioDesign Institute in Arizona. 
These three large human proteome array types - ProtoArrayTM, HuProtTM and NAPPAs – 
provide a valuable resource for the screening of enzyme substrates and high-affinity protein-
protein interactions, and for epitope mapping. However, these array types have proven more 
difficult to use for the screening of weaker protein-protein interactions that are driven by PTMs, 
which generally display binding constants in the low µM range. This issue can be mitigated 
to some degree by arraying much higher concentrations of the protein region that interacts 
with the PTM motif. Furthermore, when making the recombinant proteins for the content of 
microarrays, there is the concern that the proteins will not express well in bacteria, yeast or 
insect cells, especially when attempts are made to generate full-length proteins that can be 
rather large and prone to precipitation and inclusion body formation. This concern can largely 
be alleviated by using protein domains. The nature of protein domains (small, well-expressed, 
tightly folded and functionally stable) make them ideal for expression as recombinant proteins 
that can be used for multiplexing. We were among the first groups to develop and use protein 
domain microarrays in the early 2000s (Espejo et al., 2002, Espejo and Bedford, 2004b), and 
their use has rapidly evolved over the past two decades. At MD Anderson Cancer Center we 
have developed a core facility – the Protein Array and Analysis Core (PAAC) – to generate 
libraries of different recombinant domains and array these libraries for discovery purposes. 
 
3.4 THE DESIGN OF PROTEIN DOMAIN MICROARRAY FOR THE PAAC 
The first step in generating protein domain microarrays is identifying all the domain types that 
need to be generated for a particular project. This is done with the aid of web-based programs 
that can predict the presence of protein domains in the proteins of interest, including EMBL 
Pfam and InterPro, NCBI Conserved Domain and the CST PhosphoSite. Often, multiple 
domains of the same type or of different types will lie close together. If this is the case, we 
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select these different domains together, if they are within 50 amino acids of each other. The 
second step is to design and generate expression vectors for all of the domains that will be 
included on the arrays. Usually, we add 20 amino acids of flanking sequence to each domain, 
and then order commercial gene synthesis and cloning of the domain. We use a Canadian 
company, Biomatik, for this step. Importantly, all the domains that the PAAC designs are from 
human proteins, and for the gene synthesis, we codon optimize these human sequences for 
bacterial expression. Once the expression vectors are in-hand, the third step is to generate 
the recombinant protein domains that will serve as the content for the array. Protein domains 
of interest are made as N-terminal GST fusions. We do not use a high-throughput approach 
for recombinant GST-domain production. Finally, the purified recombinant protein domains 
are robotically arrayed onto nitrocellulose-coated glass slides (Oncyte®Avid slides, Grace 
Bio-Labs, Bend, OR), using an Aushon 2470 pin microarrayer.  
 
The recombinant proteins in the “source” plate are at a concentration of 1µg/µl, and we have 
empirically determined that repeated arraying (five times) onto the same spot results in a 
strong signal, while retaining the integrity of the spotted protein. We are not sure how much 
protein is actually immobilized on the array. Duplicates of each protein domain are used to 
facilitate identification and reproducibility. Once an array is generated it is stored at 4 °C, and 
a probe is then prepared. The arrays can be stored for at least one month at 4 °C without 
losing their binding specificity. In our hands, long-term storage of arrays for up to a year at -
80 °C has also been successful. 
 
3.5 PROBE PREPARATION FOR PROTEIN DOMAIN MICROARRAY INTERROGATION 
Protein domain microarrays can be probed with peptides, full-length tagged proteins, protein 
complexes, recombinant nucleosomes, small molecules, DNA and RNA. The probes are 
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usually biotinylated, which facilitates labeling, but epitope tagged proteins can also be used. 
The protein domain microarrays are primarily used to identify protein interactions that are 
driven by PTMs, and for these cases we use biotinylated peptide probes. Peptide probes are 
designed to have eight residues on either side of the amino acid that is carrying the PTM 
(thus 17-mer peptide) with a biotin moiety attached to either the C- or N-terminal residue. If a 
small molecule is used as a probe, the compound of interest is synthesized with a PEG linker 
and biotin. A streptavidin-fluorophore (usually Cy3 or Cy5) conjugate is then coupled to the 
biotinylated probe. The array slides are then blocked, probed and washed. This probing is 
performed in a small slide holder in a volume of 1.5 ml. In this volume we use 50-100µg of 
peptide (or recombinant protein) as a probe. The probed slides are then air dried and the 
fluorescent signal is detected using a GenePix 4200A Microarray Scanner (Molecular 
Devices). The workflow is shown in Figure 2, and additional details have been published 




Figure 2. Principles for protein domain microarray screening. Different domains are 
immobilized on a nitrocellulose-coated glass slide as GST fusion proteins. Biotinylated 
peptides (100µg) with specific PTMs are pre-conjugated with streptavidin fluorophores. 
Peptide probes are incubated with the microarray followed by washes to remove unbound 
materials. Interactions are visualized by detecting fluorescent signals. Within a block, we array 
a duplicate of each protein, and each pair of spotted proteins is arrayed at a unique angle 
(not adjacent to one another) to facilitate rapid unambiguous identification.  
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3.6 USING DOMAIN MICROARRAY TO IDENTIFY NOVEL PROTEIN INTERACTIONS 
3.6.1 Domain arrays that “read” Ubiquitin 
Ubiquitin is a highly conserved 76 amino acid protein that can be attached (though its C-
terminal glycine residue) to lysine residues in substrates by an enzyme cascade. The 
reversible attachment of a single ubiquitin (monoubiquitylation) was initially discovered forty 
years ago as a modification of histone proteins (Goldknopf et al., 1977), where it controls 
chromatin structure and regulates transcription rates. Ubiquitin itself harbors seven lysine 
residues that can all serve as attachment sites for further ubiquitin molecules, thereby forming 
polyubiquitin chains (Yau and Rape, 2016). There are at least twenty distinct families of 
structurally unique ubiquitin binding domains (UBDs) (Dikic et al., 2009). UBDs bind ubiquitin 
with relatively low affinity (10-500 µM range). However, UBDs are often repeated in proteins, 
which can result in an avidity effect that promotes strong interactions. Furthermore, long 
ubiquitin chains provide the perfect scaffold for the binding of multiple UBD-containing 
proteins and the rapid assembly of ubiquitin chain driven signaling nodes. Moreover, the 
varying topologies of the different chains provide distinct binding surfaces for UBDs. The first 
UBD to be identified and characterized was a domain in the S5a protein, which is a 
component of the 26S proteasome (Deveraux et al., 1994). S5a has two independent 
ubiquitin-interacting motifs (UIMs), and bioinformatics analysis uncovered this domain in a 
number of other proteins. UIMs thus form the founding family of UBDs, but many more 
structurally distinct UBD families have now been identified. The second largest family of UBDs 
to be identified was the ubiquitin-associated domains (UBAs) (Bertolaet et al., 2001, Wilkinson 
et al., 2001). Subsequent screens using the yeast two-hybrid approach with ubiquitin and 
ubiquitinated proteins as bait, identified the CUE domain (Shih et al., 2003), GAT domain 
(Shiba et al., 2004), VHS domains (Yamakami et al., 2003) and PAZ domains (Hook et al., 
2002). Other approaches identified PFU, UBM, UBZ and JAB/MPN domains (Fu et al., 2009b, 
Bienko et al., 2005, Bellare et al., 2008) as effectors of ubiquitinated proteins. Structural 
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studies have revealed that different surfaces of ubiquitin are targeted for non-covalent 
interactions by different UBDs, with the most common interaction surfaces centered on a 
hydrophobic patch around Ile44, an acidic region around Asp58, and Gly76 at the C-terminus 
(Scott et al., 2015). Importantly, some UBDs recognize sequences adjacent to the isopeptide 
linkages, which differ for each chain type, and thus generate chain selective UBD binders. 
Another way to achieve ubiquitin-linkage specific binding is for a protein to harbor tandem 
UBDs that are spaced for optimal engagement of one chain type and not another (Sims and 
Cohen, 2009). Additionally, PTMs on ubiquitin itself can regulate interactions with UBDs (Yau 
and Rape, 2016). The PAAC has recently generated an array of 169 recombinant ubiquitin-
binding domains, which is being used to identify 1) the readers of mono-Ub marks, 2) chain-
specific readers, and 3) the role that phosphorylation and acetylation of ubiquitin itself plays 
on regulating UBD interactions. 
 
3.6.2 Domain arrays that “read” methylated motifs 
Whereas the 1990s was the decade for identifying domains that “read” phospho-marks, the 
first decade of the new millennium was dedicated to the discovery of readers of the histone 
code. The histone code hypothesis was proposed by Strahl and Allis in 2000 (Strahl and Allis, 
2000b) and refined a year later to include the concept of effector proteins or readers 
(Jenuwein and Allis, 2001b). The Jenuwein lab identified Chromo domains as the first readers 
of methyllysine marks on histone tails (Lachner et al., 2001). This led to a flurry of activity in 
the field, with the subsequent descriptions of Tudor domains (Huyen et al., 2004, Huang et 
al., 2006b), WD40 repeats (Wysocka et al., 2005), PHD domains (Shi et al., 2006), MBT 
domains (Kim et al., 2006b, Trojer et al., 2007), PWWP domains (Wang et al., 2009b), BAH 
domains (Kuo et al., 2012) and ankyrin repeats (Collins et al., 2008) as methyl-mark readers. 
During this period, we developed a protein domain microarray to rapidly read the histone code 
(Kim et al., 2006b). We have also used this array approach to discover TDRD3 as a Tudor 
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domain effector of methylarginine marks on histone tails (Yang et al., 2010). Similar array 
approaches were developed to identify methyl-mark readers in yeast (Shi et al., 2007) and 
plants (Zhao et al., 2017). These methyl-reading arrays have also been used to identify 
readers of non-histone proteins (Levy et al., 2011, Zhang et al., 2016). The PAAC has 
generated a methyllysine binding array that contains 308 potential Kme reader domains, 
including 33 chromodomains, 43 Tudor domains, >100 PHD, as well as representatives from 

























CHAPTER 4: INVESTIGATION OF PLAA AS A NOVEL H2BUB1 READER PROTEIN 
4.1 INTRODUCTION 
Histone H2Aub1 and H2Bub1 are two critical epigenetic marks with opposite transcription 
regulation functions and they play distinct roles in DNA damage response pathways. There 
are two known H2Aub1-specific reader proteins, RSF1 and JARID1, but no H2Bub1 effectors 
have yet been identified. Thus, the effector modules' identities for these two marks remain 
largely unknown. The identification and characterization of specific effectors are essential to 
understand the mechanisms of how H2Aub1 and H2Bub1 transduce the molecular signals to 
their downstream protein complex. In the current study, I hypothesize that there are additional 
specific reader proteins for H2Aub1 and H2Bub1 that have yet to be discovered. Using an in-
house developed ubiquitin-binding domain microarray, I started the project by searching for 
specific reader proteins for either H2Aub1 or H2Bub1 and characterizing their potential 
functions as effectors of these two epigenetic marks. 
 
4.2 RESULTS AND DISCUSSIONS 
Identification of novel H2Aub1- and H2Bub1-specific reader proteins 
To identify potential H2Aub1- and H2Bub1-specific reader proteins, we used the H2Aub1 and 
H2Bub1 probes to interrogate an in-house ubiquitin-binding domain microarray that harbors 
GST fusions of known and predicted ubiquitin binders. By comparing the binding profiles, 
HRS/HGS (UIM domain) was identified as a potential H2Aub1-specific domain, and PLAA 





Figure 3: Identification of novel H2Aub1- and H2Bub1-specific reader proteins using 
ubiquitin binding domain microarray. Top: H2Bub1 probe structural information (left) and 
the UBD binding profile (right). HGS/HRS UIM domain was highlighted with a circle number 
1. Bottom: H2Bub1 probe structural information (left) and binding profile with UBDs (right). 





Validation of novel interactions using in vitro binding assays 
Cari Sagum performed a peptide pull-down assay to confirm the interactions identified using 
the protein domain microarrays. H2Aub1 and H2Bub1 were used to pull down the GST fusions 
of ubiquitin-binding domains from HRS/HGS, ANKIB1, PLAA, UBAC2 and AMFR. GST served 
as a negative control. UBAC2 and AMFR served as positive controls as both domains 
interacted with H2Aub1 and H2Bub1 probes in our microarray results. Consistent with the 
array data, HRS/HGS UIM interacted with H2Aub1 but not H2Bub1, while ANKIB1 UIM 
domain and PLAA PFU domain specifically interacted with H2Bub1 but not H2Aub1 probe 
(Figure 4A). 
 
The next step was to test whether GST-fused UBDs could preferentially interact with full-
length H2Aub1 or H2Bub1 from acid purified histone extracts. I first validated H2Aub1 and 
H2Bub1 antibodies' specificity using the ATXN7L3 knockdown (KD) cell lines, generously 
provided by Dr. Sharon Dent's group. ATXN7L3 is the adapter protein that activates three 
H2Bub1 deubiquitinating modules, USP22, USP51, and USP27X (Atanassov et al., 2016). 
Depletion of ATXN7L3 leads to increased global H2Bub1 levels without changing H2Aub1 
levels. Consistent with published results (Atanassov et al., 2016), the H2Bub1 antibody 
detected significantly increased signals in ATXN7L3 knockdown cells but no changes of 
H2Aub1 levels compared to the control cells. (Figure 5A). 
 
I then tested whether the three GST-fused UBDs could pull down their preferential 
ubiquitinated histones from acid purified histones. HRS/HGS UIM domain didn't enrich 
H2Aub1 nor H2Ub1 from histone extracts thus was excluded from the following study. ANKIB1, 
PLAA, AMFR, and UBAC2 all displayed comparable binding properties towards H2Aub1 and 
H2Bub1, in this pull-down assay. All four UBDs interacted more strongly with H2Bub1 than 





Figure 4: Validation of novel Interactions using peptide pull-down assays. This data was 
generated by Cari Sagum and is used with her permission. Top panel: 5% input of all tested 
GST proteins. Middle panel: HRS/HGS, UBAC2, and AMFR were pulled-down by the H2Aub1 








































































































    
 
 
Figure 5: Characterization of H2Bub1 antibody and validation of novel interactions 
using pull-down assays. (A) Histones were acid purified from ATXN7L3 KD, and control (CT) 
cells were separated by SDS-PAGE and followed by western blot analysis for H2Aub1 and 
H2Bub1 levels. Ponceau staining serves as a loading control. 293T GipZ CT: control cell lines 
transduced with the Non-Silencing Control Vector. 293T DUB KD: cell lines transduced with 
ATNX7L3 shRNA lentiviral vector. (B) GST-fused UBDs were used to pull down 
H2Aub1/H2Bub1 from acid purified histone extracts. GST and Beads only served as negative 












































































































Characterization of anti-PLAA and anti-ANKIB1 antibodies 
To facilitate experiments in cells, I characterized the antibodies against PLAA and ANKIB1 
using overexpression of GFP-fused PLAA and ANKIB1 in MCF-7 cells. As shown in Figure 6, 
both antibodies showed excellent specificity by recognizing the GFP-tagged and endogenous 
PLAA and ANKIB1. Ectopic expression of GFP-PLAA is significantly more abundant than 
endogenous PLAA, a 78 kDa protein labeled by a red arrow.  
 
I also examined the subcellular localization of PLAA and ANKIB1 using immunofluorescence 
microscopy. As shown in Figure 7, PLAA mainly exists in the nucleus and less in the cytosol. 
ANKIB1 is localized in the cytosol. Considering they are potential reader proteins for H2Bub1, 





           
Figure 6: Characterization of PLAA and ANKIB1antibodies using ectopic expression of 
GFP fusion proteins. GFP-PLAA and GFP-ANKIB1 were overexpressed in MCF-7 cells. 
Untransfected cells serve as negative controls. Whole-cell lysates were separated by SDS-
PAGE followed by western blot analysis against PLAA, ANKIB1, and beta-actin. The red arrow 




























































Figure 7: Sub-cellular localization of PLAA and ANKIB. MCF-7 cells were fixed with 4% 
formaldehyde, and stained for PLAA, ANKIB1, F-actin and DAPI. Immunofluorescence was 
detected using a Carl Zeiss LSM880 microscope equipped with an Aryscan confocal 




Validation of PLAA-H2Bub1 interaction using nucleosome binding assays 
Recombinant nucleosomes have become widely used to characterize epigenetic writers, 
readers, and erasers, in biochemical and structural studies (Kim et al., 2020, Chen et al., 2015, 
Zhang et al., 2017a). Testing the binding potential of nucleosomes is important because in 
some cases effector proteins can read short linear motifs and even free histones, but are 
unable to dock onto histones in the context of tightly packed nucleosomes, due to structural 
interference from other histone or DNA. Dr. Zu-Wen Sun from EpiCypher generously provided 
three types of recombinant nucleosomes, unmodified, H2Aub1, and H2Bub1 containing 
nucleosomes. The DNA that is wrapped around these recombinant nucleosomes is 
biotinylated, which serves at a tag for immobilization and detection. Before performing 
nucleosome binding assays, I characterized these nucleosomes using Coomassie staining 
and western blot. As shown in Figure 8A, the H2Aub1 nucleosome contains H2Aub1, H2B, 
H3 and H4 but no H2A, while the H2Bub1 nucleosome contains H2A, H2Bub1, H3 and H4 
but not H2B, indicating that the respective nucleosomes contain fully ubiquitinated H2A and 
H2B. H2Aub1 and H2Bub1 were also detected by the corresponding antibodies (Figure 8B), 
confirming that three recombinant nucleosomes consist of high-quality core histones with the 
proper ubiquitination marks because H2Aub1 and H2Bub1 antibodies recognize the 
branching region where ubiquitin forms an isopeptide with the H2A at K119 and H2B at K120 






Figure 8: Characterization of recombinant nucleosomes. Three recombinant 
nucleosomes (unmodified, H2Aub1 and H2Ub1) were separated by SDS-PAGE and subject 
to Coomassie staining (A) and western blot for H2Aub1, H2Bub1 and H3 (B). Histone extracts 











































I then tested whether the PLAA PFU domain can specifically interact with H2Bub1 in the 
context of nucleosomes (Figure 9). GST-PFU domain pulled down H2Bub1 specifically from 
histone extracts but didn't interact with H2Bub1 nucleosomes, suggesting this interaction 
might require additional chromatin context missing in recombinant nucleosomes, or 
alternatively, the PFU domain interacts with free H2Bub1 but not with nucleosomal H2Bub1. 
 
Notably, GST-PFU also pulled down unmodified H2B from histone extracts. As seen in Figure 
5B, ponceau staining showed that unmodified core histones were pulled down together with 





Figure 9. Testing the PLAA-H2Bub1 interaction using nucleosome binding assays. GST 
and GST-PFU proteins were incubated with three recombinant nucleosomes and histone 




Generation of PLAA Knockout MCF-7 Clones 
To interrogate functions of PLAA in vivo, I generated four single cell-derived PLAA knockout 
(KO) MCF-7 clones using CRISPR/Cas9. Unlike Doa1, PLAA depletion didn't affect the 
amount of free ubiquitin in the whole-cell extracts. Surprisingly, I observed a 15 kDa protein 
accumulated that can be recognized by the anti-ubiquitin antibody in PLAA KO cells and 
named it 15UBL protein (Figure 10A). Cellular fractionation assays showed 15UBL exists in 
the  cytoplasm (Figure 10B). I also tested how non-specific inhibition of DUBs affected 15UBL 
using PR-619, which is a broad spectrum DUB inhibitor (Seiberlich et al., 2012). PR-619 
treatment caused slight upregulation of 15UBL in PLAA KO cells but had no effects on WT 
cells, suggesting PLAA is indispensable for 15UBL's turnover by DUBs (Figure 10C). It 
remains unknown which DUBs mediate hydrolysis of 15UBL. 
 
Western blot analyses ruled out K48- and K63-linked di-Ub, RPS27A and interferon-
stimulated gene 15 (ISG15) (data not shown). RPS27A is one of two ribosomal proteins 
containing an N-terminal ubiquitin and a c-terminal ribosomal protein S27A(Redman and 
Rechsteiner, 1989). ISG15 is a ubiquitin-like protein induced upon type I interferon treatment 
(Korant et al., 1984, Blomstrom et al., 1986). Both RPS27A and ISG15 have molecular 
weights of around 15 kDa and can be recognized by the anti-ubiquitin antibodies. We are still 
not sure of the identity of this protein. 
 
PLAA depletion also led to a major decrease in H2Aub1 and H2Bub1. H3K4me3, which can 
be promoted by H2Bub1 during transcription activation (Kim et al., 2009, Racine et al., 2012), 
was not affected in PLAA KO cells (Figure 11A). In yeast, Doa1 depletion abolishes PCNA 
ubiquitination upon DNA damage (Lis and Romesberg, 2006). However, upregulation of 
PCNA ubiquitination after UV-induced DNA damage treatment was not affected in PLAA KO 






Figure 10: PLAA knockout clones 
generated using CRISPR/Cas9 and 
characterization of 15UBL. (A) Western blot 
analysis of WT and four PLAA KO clones for 
PLAA, beta-actin, and ubiquitin. These four 
clones were labeled as 3-4, 3-5, 3-8, and 3-9 
because they were different clones selected 
from plate #3 generated using the same 
sgRNA targeting Exon1 of PLAA. (B) 
Subcellular fractionation assay showing 
15UBL localization in the cytosol. LDH and 
Lamin A/C served as loading controls for 
cytosol and nuclear fractions, respectively. (C) 
WT and PLAA KO clone 3-5 were treated with 
10 µM PR-619 for 24 hours. Whole-cell 
lysates were subjected to western blot 
analysis using antibodies against ubiquitin, 










                                                                       
Figure 11: Effects of PLAA depletion on histone and PCNA ubiquitination. Histone 
extracts (A) and whole-cell lysates (B) from wild type and PLAA KO clone (3-5) were 
separated by SDS-PAGE and subjected to western blot analysis. B: Both WT and KO cells 




PLAA’s function in DNA damage repair 
Given that Doa1 facilitates DNA damage response (DDR) by supplying free ubiquitin to the 
DNA replication and repair machinery (Lis and Romesberg, 2006), I asked whether PLAA is 
also involved in DDR. I used laser microirradiation followed by immunofluorescence and live-
cell imaging to determine the recruitment of PLAA and H2Bub1 to DNA damage sites. Upon 
UV-induced DNA damage, PLAA was enriched at DNA double-strand breaks (DSBs) as 
evidenced by its co-localization with γH2AX and RFP-tagged 53BP1. PLAA was enriched, but 
H2Bub1 was excluded at the DNA damage stripes 15 min post-irradiation (Figure 12A & 12B). 
As PLAA and H2Bub1 antibodies require different fixation methods, I could not perform co-
staining using both antibodies. PLAA's recruitment at DSBs was also observed using live-cell 
imaging. GFP-tagged PLAA was enriched at DSBs indicated by RFP-tagged 53BP1. It's 
unclear whether PLAA's recruitment to DSBs was dependent on H2Bub1, as PLAA interacts 
with other DDR-related proteins, including VCP (Acs et al., 2011). 
 
PLAA forms homo-multimer and interacts with VCP   
Effector proteins often dimerize or multimerize to create avidity effects, thus enhancing their 
binding affinities with substrates (Hjerpe et al., 2009). I tested whether PLAA can also form 
oligomers in vivo by co-immunoprecipitation. I co-expressed 3xFlag tagged PLAA and GFP-
fused PLAA full-length and four truncated proteins, WD40-PFU (G-W-P), PFU (G-P), PFU-
PUL (G-P-P), and PFU deletion (G-PFUΔ). Co-immunoprecipitation results showed that PUL 
domain is required for PLAA oligomerization while the WD40 and PFU domains are 
dispensable.  
 
Doa1 interacts with Cdc48 directly via its C-terminal PUL domain. I asked whether PLAA-VCP 
interaction was conserved in mammalian cells. Consistent with previous studies (Decottignies 
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et al., 2004, Ghislain et al., 1996, Ogiso et al., 2004, Mullally et al., 2006), PLAA interacts with 
VCP and PUL domain is required for this interaction (Figure 13). 
 
 
Figure 12. PLAA localizes to, and H2Bub1 is removed at DNA damage sites. (A) PLAA 
localizes to sites of laser-induced DNA damage in MCF-7 cells. DNA damage was induced by 
laser microirradiation followed by immunofluorescence (15 min after damage) with indicated 
antibodies. γH2AX marks the 'laser lines' containing damaged DNA. (B) H2Bub1 is decreased 
at DNA damage sites in MCF-7 cells. DNA damage was induced as in (A), followed by 
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immunofluorescence for H2Bub1 and γH2AX. (C) Accumulation of GFP-PLAA and RFP-






Figure 13. PLAA forms oligomers and interacts with VCP. (A) PLAA has an N-terminal 
WD40 domain, PFU domain and a C-terminal domain. (B) 3xFlag-PLAA and GFP-tagged full-
length and truncated PLAA were co-transfected in 293T cells. G-W-P-P: full-length PLAA, G-
W-P: GFP-WD40-PFU, G-P: GFP-PFU, G-P-P: GFP-PFU-PUL, G-PFUΔ: GFP-WD40-PUL. 
GFP trap was used to coimmunoprecipitate 3xFlag-tagged PLAA and VCP. GFP only was 
used as a negative control. 5% Input and immunoprecipitates were detected 




CHAPTER 5: HISTONE H3 N-TERMINAL MIMICRY DRIVES A NOVEL NETWORK OF 
METHYL-EFFECTOR INTERACTIONS 
Part of this chapter is based upon: J. Chen, C. Sagum, J. Zhou, J. Horton J, X. Cheng3 and 
M.T. Bedford, Histone H3 N-terminal mimicry drives a novel network of methyl-effector 





This study seeks to address whether there are proteins in the human proteome that have an 
H3-like N-terminal motif and whether they can interact with known H3K4me3-reader proteins 
in a methylation-dependent manner, which could dramatically expand the PHD interaction 
network. H3 N-terminal mimicry proteins (H3TMs) are defined as proteins that start with an 
iM-Z1-R2-X3-K4 sequence motif. In this motif, iM is the initiator methionine, and Z1 represents 
one of the seven amino acids that allows for iMet cleavage, and X3 represents any amino 
acid. First, we searched the database for proteins that harbor this relaxed motif when it is 
positioned just after the iMet residue, and we identified 48 H3TMs. We chose seven of these 
H3TMs as candidates for further in vitro validation experiments. Next, we used an in-house 
methyl reader domain microarray, which harbors over 200 methyl effector domains, and 
identified trimethylation-specific interactions between the seven H3TMs and eight arrayed 
PHD fingers (and one Tudor domain-containing protein). We validated a sub-set of these 
interactions by both peptide pull-down of recombinant GST-fusion proteins and their 
endogenous counterparts from total cell lysates. Using the same pull-down approach, we 
further show that a number of the unmethylated H3TMs interact with the NURD complex. We 
also explored the possibility that the K4 site of H3TMs could be post-translationally modified 
by three known H3K4 methyltransferases: Set7/9, PRDM9 and the MLL1 complex. This study 
demonstrates that K4 methylation of H3TMs promotes a new interaction network with PHD 




5.2 RESULTS AND DISCUSSIONS 
Bioinformatic search for histone H3 N-terminal mimicry proteins 
To identify H3 N-terminal mimicry proteins that undergo initial methionine cleavage and 
contain RxK motifs, we searched for M-Z-R-X-K motif-containing proteins using the Motif 
Search database (https://www.genome.jp/tools/motif/MOTIF2.html). Z represents alanine, 
glycine, serine, cysteine, threonine, proline, or valine, which is a critical component of this 
motif because these seven amino acids are permissive for initiator methionine cleavage at the 
P1’ position (Sherman et al., 1985, Frottin et al., 2006, Wingfield, 2017a). X represents all 20 
possible amino acid residues. We excluded histone H3 variants from the results and identified 
257 M-Z-R-X-K motif-containing proteins, which harbored this motif in either the body of the 
protein or at the protein’s N-terminus. About 1/5 of these proteins have the motif restricted to 
their N-terminus; specifically, 48 of these proteins possessed the motif at their N-termini 
(Figure 14A, lower panel), while the remaining 209 proteins possessed the motif at the 
internal regions (Figure 14A, middle panel). Functional annotation by the Panther database 
(http://pantherdb.org/) shows that the slice of the pie chart represented by “chromatin-binding 
protein” (Figure 14A, upper panel) does not increase if the M-Z-R-X-K motif is internal. 
However, if the iM-Z-R-X-K motif was restricted to the N-terminus of proteins, there was a 
dramatic enrichment of proteins that are functionally annotated as “chromatin-binding protein” 
(Figure 14A, blue wedge). These results indicate that there is a dramatic enrichment of 
“chromatin-binding protein” class in H3TMs, which indicates that these types of proteins 
(transcription factors and transcriptional co-regulators) may engage the PHD interaction 
network. 
 
Phylogenetic analysis of the 48 proteins that harbor iM-Z-R-X-K motifs, identified several 
families of transcriptional factors with conserved N-terminal sequences: MEF2A/B/C/D, 
SALL1/2/3/4, BCL11A/B, FOG1/2, and TSHZ1/2/3 (Figure 14B). Notably, SALL1(Lauberth 
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and Rauchman, 2006), FOG1 (Hong et al., 2005, Svensson et al., 2000), and BCL11A/B 
(Dubuissez et al., 2016b, Moody et al., 2018) are known to interact with the NuRD corepressor 
complex via their N-termini. We chose one protein from each of the families, MEF2C, BCL11B, 
and TSHZ1, to perform follow-up studies. VRK1 is a nuclear serine/threonine kinase that 
phosphorylates several essential proteins including p53/TP53, histone H3, BANF1, and ATF2 
(Nichols et al., 2006, Lopez-Borges and Lazo, 2000, Sevilla et al., 2004, Kang et al., 2007). 
Importantly, VRK1 K4me1 has been identified using mass spectrometry (MS) implying K4 
residue is likely a target for methylation in vivo (Wu et al., 2015). PCLAF interacts with PCNA 
to regulate DNA repair during DNA replication (Povlsen et al., 2012, Kais et al., 2011). MAPK8 
is another serine/threonine kinase that involves cell proliferation, differentiation, migration, and 
apoptosis (Kurokawa et al., 2000, FLEMING et al., 2000, Gupta et al., 1996, Dai et al., 2000, 
Miotto and Struhl, 2011, Tomlinson et al., 2010). HIVEP1 is a zinc-finger protein that binds to 
the HIV-1 enhancer to activate HIV-1 gene expression (Maekawa et al., 1989). Thus, we 
selected seven H3TMs candidates for further evaluation, because of their distribution across 
the phylogenetic tree and their roles in transcriptional regulation: VRK1, BCL11B, TSHZ1, 
MEF2C, PCLAF, MAPK8, and HIVEP1 (Figure 14C). Then, we screened for potential novel 





Figure 14. Identification of H3 N-Terminal Mimicry Proteins. A) PANTHER Protein Class 
annotation of 20996 proteins in the human proteome, 209 internal motif-containing proteins, 
and 48 N-terminal motif-containing proteins (excluding histone H3 and variants). B). 
Phylogenetic analysis of the N-terminal sequences of 48 H3TMs and histone H3. Red 
asterisks indicate seven H3TMs candidate for follow-up study and their N-terminal sequences 




Identification of H3TMs interactions with methyl-lysine effector domains 
To identify potential interactions between the 7 candidate proteins and methyl-reading 
domains, we synthesized N-terminal peptides (2-13 amino acids excluding the initial 
methionine) with and without tri-methylation at the K4 position. We used these biotinylated 
peptides as probes to interrogate an in-house methyl-reader microarray that harbors GST 
fusions of known and predicted binders of methyl-lysine and methyl-arginine marked motifs 
(Chen et al., 2020). The current array contains 108 PHD, 40 Tudor, and 31 Chromo domains. 
As positive and negative controls, the histone H3K4me3 peptide interacted with known 
H3K4me3-interacting PHD finger domains and Tudor domains, while the unmodified peptide 
did not (Figure 15, top left panel). Interestingly, each of the seven peptide probes that 
harbored the K4me3 mark (Figure 14C) displayed a unique interaction profile with known 
H3K4me3-interacting PHD finger domains (Jain et al., 2020), and many of these peptides 
were also recognized by the Tudor domain-containing protein SPIN1, which is a well 
characterized H3K4me3 reader (Yang et al., 2012). Notably, compared to the other probes, 
VRK1 and BCL11B had a greater number of interacting reader domains. When the K4 position 
was tri-methylated, both VRK1 and BCL11B interacted with PHF2, TAF3, and KDM7A PHD 
fingers; however, VRK1 selectively interacted with DIDO1, ING1/2, and MLL5 PHD fingers, 
while BCL11B selectively interacted with ING3 and PHF23 PHD fingers. The TSHZ1 K4me3 
peptide bound the PHD fingers of TAF3 and ING3, and PCLAF only interacted with KDM7A. 
Also, as six of the seven methylated peptide probes interacted well with the arrayed SPIN1 






Figure 15. Identification of novel methylation-dependent interactions between H3TMs 
and PHD fingers using a methyl reader domain microarray. N-terminal peptide probes 
without (not shown) and with K4me3 for 7 H3TMs and histone H3 were probed onto our 
methyl-reader microarray. Duplicates of each protein domain were used to facilitate 
identification and reproducibility. Only methylation-specific interactions were selected for 




Validation of novel interactions using in vitro interaction assays  
We used a peptide pull-down assay to confirm a small subset of the interactions we observed 
on the protein domain microarrays, and to validate the methyl-dependent nature of these 
bindings. GST fusions of PHD domains from PHF2, ING2 and ING3, and the Tudor domain 
of SPIN1 were used to perform pull-downs with biotinylated VRK1, BCL11B, TSHZ1 and 
histone H3 peptide pairs, in either methylated or unmethylated forms. The PHF2 PHD finger 
strongly interacted with the methylated peptides derived from VRK1, BCL11B, and H3; 
whereas it interacted more weakly with the methylated form of TSHZ1. The ING2 PHD finger 
only bound with the methylated VRK1 and H3 peptides. ING3 showed methylation-dependent 
interactions with TSHZ1 and H3, but could also interact with VRK1 in a methyl-independent 
fashion. SPIN1 interacted with VRK1, BCL11B, TSHZ1, and H3 peptides in their tri-methylated 
forms (Figure 3A). 
 
Next, we asked if we could use the same peptide sets to pull down the full-length methyl-
effector proteins from whole-cell lysates. We performed these experiments because it is 
possible that the isolated recombinant protein domains may behave differently than the full-
length endogenous counterparts. To facilitate this experiment, we were able to identify 
antibodies that could recognize endogenous PHF2, ING2 and SPIN1, but we were unable to 
find a good ING3 antibody. The whole-cell lysates pull-downs using the VRK1 peptide sets, 
enriched for endogenous PHF2, ING2 and SPIN1, when methylated. The BCL11B methyl-
peptide enriched for endogenous SPIN1, and very weakly endogenous PHF2. The TSHZ1 
methyl-peptide only enriched for endogenous SPIN1 (Figure 16B).  
 
A number of the H3MTs listed in the phylogenetic tree (Figure 1C) harbor the ability to bind 
the NuRD repressor complex, through their N-termini. For example, SALL1 (Lauberth and 
Rauchman, 2006), FOG1 (Hong et al., 2005, Svensson et al., 2000), and BCL11A/B 
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(Dubuissez et al., 2016b, Moody et al., 2018) all possess this property, and it is thought that 
methylation at their K4 position will block this interaction just as it does for the interaction 
between NuRD and Histone H3 (Zegerman et al., 2002). It has been shown that the MTA1 is 
a core subunit of the NurD complex, and the C-terminus of MTA1 (454–715) recognizes the 
N-terminus of BCL11B (Wu et al., 2013b). We next determined whether K4me3 has the ability 
to disrupt the interactions between the NuRD complex and VRK1, BCL11B, and TSHZ1. To 
do this, we again use the peptide sets to perform pull-downs from whole-cell lysates, and we 
probed these pull-downs with antibodies against MTA1 and RBAP46/48 (another component 
of the NuRD complex). Indeed, as expected, we find that BCL11B and histone H3 peptides 
engage NuRD when unmethylated, and so does TSHZ1, which has not been reported before. 
The unmethylated VRK1 peptide does not have the ability to recruit the NuRD complex 
(Figure 16B). Thus, just like histone H3, a number of H3MTs can switch from recruiters of 
activator complexes (in their methylated state) to recruiters of the NuRD repressor complex 
(in their unmethylated state). 
 
In our pull-down assays, performed from whole-cell lysates, we noticed that substantially more 
PHF2 was enriched using the VRK1-K4me3 peptide as compared to the H3K4me3 peptide 
(Figure 16B). PHF2 PHD domain has been reported to have a binding affinity (Kd) of 230 nM 
for H3K4me3 (Horton et al., 2011), and we performed isothermal titration calorimetry (ITC) to 
determine the binding affinity of the PHF PHD finger for the methylate N-terminus of VRK1. 
As suggested by the pull-downs, we observed an almost three-fold stronger binding of PHF2 
for VRK1 than for H3K4me3 (87 nM vs 230 nM). The binding affinity of PHF2 for BCL11B was 
much weaker at 7.1 uM (Figure 16C). Thus, there are a myriad of interactions that can 
potentially occur on H3TMs, either in their methylated or unmethylated states, and the high 
binding affinity between the VRK1 K4me3 peptide and the PHF2 PHD domain suggests a 
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competition model where PHF2 might be recruited to chromatin by H3K4me3 and then 




Figure 16. Validation of novel 
interactions using in vitro 
interaction assays. A) Peptides pull 
down GST-tagged PHD fingers. 
Unmodified and K4me3 peptide 
probes for VRK1, BCL11B, TSHZ1, 
and H3 were used to pull down GST-
tagged PHF2 PHD, ING2 PHD, ING3 
PHD, and SPIN1 TUDOR. B). 
Peptides pull down endogenous PHD 
fingers and NuRD complex from 293T 
whole cell lysates. Peptides in (A) 
were used to pull down PHF2, ING2, 
ING3, SPIN1 and MTA1 and 
RBAP46/48. Immunoblot using 
streptavidin-HRP was used to ensure 
equal loading of all biotin-tagged 
peptide probes. C). Isothermal 
Titration Calorimetry (ITC) 
measurement of binding of PHF2(1-
451) to tri-methylated VRK1 (1-12) 
K4me3 peptides. Binding constant 
was calculated by fitting the data to 
one-site binding model equation 
using the ITC data-analysis module of 
Origin 7.0 (OriginLab Corporation). 
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The K4 residue of three H3TMs can be methylated by H3K4 methyltransferases in vitro 
Importantly, VRK1-K4me1 has been identified using mass spectrometry (MS) implying K4 
residue is likely a target for methylation in vivo (Wu et al., 2015). In addition, three independent 
MS studies performed by Cell Signaling Technology (CST), publicly available through the 
PhosphoSitePlus website (www.phosphosite.org), have also identified mono-methylation at 
the VRK1-K4 position. All four of these reported studies focused on enriching for Kme1 
peptides, either using methyl-specific Kme1 antibodies (CST) or using a unique chemical 
derivation approach followed by antibody enrichment, which was used by Yingming Zhao’s 
group (Wu et al., 2015). These independent studies suggest that VRK1 is indeed targeted for 
methylation at its K4 position, just like histone H4, and that higher degrees of methylation 
(me2/3) may occur. 
 
To experimentally test if H3TMs have the potential of being methylated by enzymes that 
modify the H3K4 site, we set up a number of in vitro methylation reactions. Three different 
lysine methyltransferases that have been reported to deposit methyl marks at the histone 
H3K4 position were used: Set7/9 (Wang et al., 2001), MLL1 complex (Dou et al., 2006, Song 
and Kingston, 2008) and PRDM9 (Wu et al., 2013a). We performed in vitro methylation using 
the same set of peptide pairs used in previous experiments. For each set of in vitro methylation 
reaction, enzyme and 3H-labeled Sam served as negative controls, and H3K4 peptides served 
as positive controls. We showed that Set7/9 could methylate unmodified peptides from all 
three candidate proteins VRK1, BCL11B and TSHZ1 but could not methylate the K4me3 
peptides, indicating that methylation occurs at the K4 sites (Figure 17). MLL1 and PRDM9 
can only methylate VRK1 with moderate activity, compared to H3 peptide, suggesting that 
VRK1 is a weaker substrate than histone H3 for MLL1 and PRDM9. These data support the 
hypothesis that at least a subset of H3TMs can be targeted by both the readers and writers 





Figure 17. Three H3TMs can be methylated at Lys4 by H3K4 methyltransferases. 
Unmodified and K4me3 peptide probes for VRK1, BCL11B, TSHZ1, and H3 were incubated 
with three H3K4-specific methyltransferases, Set7/9 (upper), MLL1 (middle) and PRDM9 
(lower). Enzymes and 3H-labeled Sam were used as a negative control (most right line). 





Generation of C-terminal GFP tagged H3TM Fusion Proteins 
To facilitate the characterization of 6 H3TM candidates in vivo, I designed a set of fusion 
proteins consisting of the H3TMs linked to a C-terminal GFP (Figure 18A). Besides serving 
as a purification tag, the C-terminal GFP tag keeps the N-termini of H3TMs intact and available 
for modifications and protein interactions.  
 
 All six fusion proteins showed good expression levels in 293T cells at the expected positions 
(Figure 18B). GFP fusion proteins can be efficiently purified from whole-cell lysates using a 
GFP-trap® (ChromoTek, Germany), which utilizes beads that are covalently attached to a 
nanobody that only recognizes GFP, thus removing the confounding issues of heavy or light 
chain contamination that is associated with traditional antibody-based enrichment approaches 
(Figure 18C).  
 
Subcellular localization of GFP-tagged H3TMs 
I examined the subcellular localization of six H3TM-GFP fusions in MCF-7 cells (Figure 19). 
VRK1, BCL11B, and MEF2C are exclusively in the nucleus. PCLAF and TSHZ1 displayed 
nuclear enrichment, while MAPK8 are homogeneously localized in both the nucleus and 
cytoplasm. Interestingly, BCL11B, MEF2C, and PCLAF exhibited striking punctate patterns in 








Figure 18: Design and generation of H3TM-GFP fusion proteins. (A) The cDNAs of six 
H3TMs were synthesized with codon optimization and cloned into the pEGFP-N1 vector by 
Biomatik (Ontario, Canada). (B) Overexpression of H3TM-GFP fusion proteins and GFP only 
vector in 293T cell lines. Whole-cell lysates were analyzed using western blot against GFP 
and beta-actin. Control: an untransfected control. (C) Ectopically expressed H3TM-GFP 










































































































Figure 19. Subcellular localization of H3TMs in MCF-7 cells. MCF-7 cells were transiently 
transfected with the six H3TM-GFP fusions, fixed, and stained for F-actin and DAPI. 
Immunofluorescence was detected using a Carl Zeiss LSM880 microscope equipped with an 





Mapping of H3TM K4me3 using LC-MS 
I overexpressed H3TM-GFP fusion proteins in 293T cells and purified them using the GFP-
Trap kit. The enriched samples were separated by SDS-PAGE and followed by Coomassie 
staining (Figure 18C). The dominant gel bands corresponding to the full-length GFP fusions 
were cut and sent to the Proteomics Facility at UT Austin for digestion and LC-MS analysis. 
Tryptic digestion only covered the N-terminal sequences of BCL11B and PCLAF, and no K4 
methylation was identified in these two cases. For the remaining four candidates, tryptic 
digestion was not able to generate peptides that covered the K4 position, likely because these 
regions are rich in arginine and lysine residues thus cleaved into very small fragments by 
trypsin. Digestion using GluC did not cover any N-terminal sequences of all six proteins either 
(Table 5). 
 
Failure to identify the N-terminal sequences might result from the "masking" effects caused 
by other highly abundant peptides. To overcome this obstacle, I cloned a TEV cleavage site 
into the N-terminus of VRK1, between Q11 and S12 residues. Upon TEV cleavage, the 
supernatant was supposed to contain the N-terminus of VRK1-fused with TEV site as the most 
dominant peptide, which was sent for LC-MS analysis. However, the most abundant peptide 
(peak intensity: 4E8) started with A5 residue. The second most abundant peptide started with 
K4 but had an intensity that was 300 folds less (peak intensity: 1.3E6), suggesting that VRK1 
N-terminus was subjective to endogenous cleavage that limited its capability to be mapped 
by LC-MS analysis (Table 6). Thus, using these mass spec approaches, we were unable 




Table 6. Identification of N-terminal sequences of H3TMs using LC-MS 
 N-terminal Sequence Coverage by Different Digestion Enzyme  
H3TM-GFP Fusion Trypsin GluC TEV 
VRK1 No No  
BCL11B Yes, No K4me1/2/3 No  
MEF2C No No  
PCLAF Yes, No K4me1/2/3 No  
MAPK8 No No  
TSHZ1 No No  
VRK1-TEV   
AAQAGRQENLYFQ (4E8) 
VKAAQAGRQENLYFQ (1.3E6)       






Development and initial characterization of K4me3-Specific Antibodies  
As LC-MS analysis didn't find evidence of K4me3, I developed K4me3- and N-terminus-
specific antibodies for each of the four candidates, VRK1, BCL11B, MEF2C, and TSHZ1. The 
K4 sites of these four proteins are subject to mono-methylation, acetylation, and ubiquitination 
(Wu et al., 2015, Angelelli et al., 2008, Dubuissez et al., 2016a, Schwer et al., 2009), similar 
to the H3K4 site, suggesting that they are potentially modified by tri-methylation. Antigens 
contain the first 12 amino acids without iMet and with K4me3. Two polyclonal antibodies were 
generated for each candidate through affinity purification, which recognized the K4me3 motif 
and N-terminal sequence, respectively. I first tested the antibody specificity using a dot blot 
assay. K4me3-specific antibodies only detected K4me3 peptide probes, while N-term-specific 
antibodies recognized both modified and unmodified peptide probes, indicating excellent 
specificity at the peptide levels (Figure 20A).  
 
I also tested whether these antibodies could recognize the H3TM-GFP fusion proteins. I 
generated K4A mutants for all four candidates as negative controls. I overexpressed both WT 
and K4A proteins in 293T cell lines and purified the fusion proteins using GFP-trap, followed 
by western blot analysis. As expected, all four N-term antibodies detected both WT and K4A 
signals at the calculated molecular weights. However, K4me3 antibodies for VRK1 and 
TSHZ1 recognized both WT and K4A mutant proteins, while BCL11B and MEF2C K4me3 








Figure 20. Development and validation of K4me3-specific antibodies. (A) Validation of 
antibody specificity using dot blot assays. K4me3 and unmodified peptide probes were blotted 
onto the membrane with decreasing concentrations, 5, 2.5, 1.25, 0.5, and 0.25 µg. Duplicate 
membranes were prepared and probed with the indicated antibodies. (B) Overexpression of 
VRK1-GFP, BCL11B-GFP, TSHZ1-GFP, and MEF2C-GFP proteins (WT vs. K4A) in 293T 
cells. H3TM-GFP proteins were immunoprecipitated using GFP-Trap and analyzed by 
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Characterization of VRK1 K4me3-Specific Antibody 
Results from Figure 20 suggested that the VRK1 K4me3 antibody had non-specific binding 
activity towards unmodified VRK1 full-length protein. I then tested the specificity of the VRK1 
K4me3 antibody using the VRK1 unmodified peptides and H3K4me3/unmodified peptides. 
Both VRK1 K4me3 and H3K4me3 peptides strongly interacted with the tested antibody, 
though VRK1 K4me3 was used as the immunogen. VRK1 K4me3 antibody displayed pan-
me3 binding affinity. Unmodified VRK1 and H3 peptides pulled down a small amount of the 
tested antibody compared to Kme3 peptides (Figure 21A), suggesting that this polyclonal 
antibody had a non-specific binding affinity towards the unmodified VRK1 and H3 N-terminal 
motifs. Along with the observations from Figure 20A, the antibody's inadequate specificity 
prevented its application in qualitative validation of the VRK1 K4me3 mark in vivo. 
 
To improve the specificity of the VRK1 K4me3 antibody, I developed two negative depletion 
methods. Method 1 was based on dot blot assay. VRK1 K4me3 antibody was incubated 
overnight with a membrane containing 60 dots of VRK1 unmodified peptide (5 µg peptide per 
dot) before being used for western blot analysis. Method 2 involved preincubation of 2 µL 
VRK1 K4me3 antibody with 10 µg VRK1 unmodified peptides in a total volume of 20 µL for 1 
hour at room temperature. Without depletion treatment, VRK1 K4me3 recognized both WT 
and K4A mutant proteins. In contrast, antibodies treated with two depletion methods could not 
detect either WT or K4A mutant proteins after the same exposure times (Figure 21B). These 
results suggested GFP-VRK1 was not trimethylated at the K4 site under the current 
experimental conditions. The K4me3 antibody was pretreated using method 2 before western 






Figure 21 Characterization of VRK1 K4me3 antibody and Negative Depletion Treatment  
(A) VRK1 and Histone H3 peptides (unmodified and K4me3) were used to pull down the VRK1 
K4me3 antibody. The samples were separated by SDS-PAGE and analyzed using western 
blot with the anti-Rabbit secondary antibody. (B) Comparison of two negative depletion 
methods. VRK1-GFP (WT and K4A) fusion proteins were overexpressed in 293T cells and 
purified using GFP-Trap. Three membranes were probed with untreated and treated 
antibodies. Left: untreated antibody. Middle: method 1: 2 µL antibody was pretreated with a 
membrane blotted with 60 VRK1 unmodified peptide dots (5 µg peptide per dot) overnight at 
4°C. Right: method 2: 2 µL antibody was incubated with 20 µg of unmodified VRK1 peptides 
for 1 hour at room temperature.   
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After improving the VRK1 K4me3 antibody specificity by negative depletion, I further 
characterized this antibody using VRK1 knockdown and overexpression of VRK1-GFP 
proteins. VRK1 knockdown and overexpression were confirmed by both the VRK1 (Sigma) 
and VRK1 N-term antibodies (Figure 22A). VRK1 (Sigma) antibody recognizes the C-
terminus of VRK1. VRK1 K4me3 detected multiple bands across four samples, and these 
signals didn't change or shift accordingly to those detected by the VRK1 N-term antibody 
(Figure 22A). I also purified endogenous VRK1 from control and VRK1 KD cells using the 
VRK1 (Sigma) antibody. Similarly, VRK1 K4me3 signals didn't decrease in VRK1 KD cells 
compared to control cells, suggesting that VRK1 K4me3 signals were false-positive signals 





Figure 22. Characterization of VRK1 K4me3 antibody using VRK1 knockdown and 
VRK1-GFP overexpression. (A) Huh-7 cells were transiently transfected with control siRNA, 
VRK1 siRNA, WT VRK1-GFP and K4A-GFP plasmids. Whole-cell lysates were separated by 
SDS-PAGE and analyzed by western blot against VRK1 (Sigma), beta-actin, VRK1 K4me3 
(after negative depletion) and VRK1 N-terminus. (B) Huh-7 cells were transfected with control 
siRNA and VRK1 siRNA. Endogenous VRK1 was immunoprecipitated with the  anti-VRK1 
antibody (Sigma) and analyzed by western blot using the same antibody set. At the bottom of 
membranes in (A) and (B), 2.5 ug of K4me3 (left) and unmodified (right) VRK1 peptides were 
blotted on the membrane as positive controls.  
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Detection of VRK1 K4me3 and VRK1-PHF2 interactions under various circumstances 
VRK1 has the highest expression levels in the G2/M phase and phosphorylates histone H3 at 
Thr3 and Ser10 (Kang et al., 2007). I asked whether mitotic arrest could upregulate VRK1 
K4me3 in vivo using the Nocodazole treatment. Western blot analysis of input and 
immunoprecipitated samples displayed comparable VRK1 levels and VRK1 K4me3 signals 
(Figure 23A), indicating that VRK1 K4me3 cannot be induced by mitotic arrest. 
 
Set7/9, a mono- and di-methyltransferase, can methylate the VRK1 K4 site (Hamidi et al., 
2018). I tested whether overexpression of Set7/9 could stimulate K4me3 signals and switch 
on the VRK1-PHF2 interactions by activating the VRK1 K4 site for potential tri-
methyltransferase by depositing mono- and dimethyl marks. PHF2 was not co-
immunoprecipitated by VRK1 and VRK1 K4me3 signals didn’t change across three cell lines 
(Figure 23B). RPL29K5me2 was not significantly upregulated in WT Set7/9 overexpressed 
cells, possibly resulting from high expression levels of endogenous Set7/9 in 293T cells 
(Hamidi et al., 2018). All the above results suggested that Set7/9 overexpression could not 
induce VRK1 K4me3 signals or turn on VRK1-PHF2 interactions. 
 
I also tested whether PHF2 could be co-immunoprecipitated by the WT VRK1-GFP fusion 
protein. I transiently transfected 293T cells with WT and K4A mutant VRK1-GFP and purified 
the fusion proteins using GFP-Trap and detected with the anti-PHF2 antibody. Consistent with 
Figure 23B, PHF2 was not co-immunoprecipitated with WT or K4A mutant VRK1-GFP fusions, 




Figure 23. Mapping of VRK1 K4me3 under 
various circumstances. (A) 293T cells were 
treated with Nocodazole to induce mitotic arrest. 
VRK1 was immunoprecipitated from 
unsynchronized and mitotic cells and subjected 
to western blot analysis against VRK1 (Sigma), 
VRK1 K4me3, beta-actin, Histone H3S10 
phosphorylation and H3. H3S10p served as a 
positive control for mitosis. (B) 293T cells were 
transiently transfected with empty vector (EV), 
3xFlag-tagged WT and enzymatic-dead mutant 
H297A Set7/9. VRK1 was immunoprecipitated 
from three cell lines and subjected to western 
blot analysis against PHF2, VRK1 (Sigma), 
VRK1 K4me3, beta-actin, Set7/9, Flag, 
RPL29K5me2 and RPL29. (C) 293T cells were 
transiently transfected with WT and K4A mutant 
VRK1-GFP. VRK1-GFP was immunoprecipitated 
from three cell lines and subjected to western 
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In Chapter 3 of this dissertation, I discussed the history, design and application of protein 
domain microarray as a platform to decipher novel molecular interactions. In Chapters 4 and 
5, I described application of two protein domain microarrays, ubiquitin-binding domain and 
methyl reader domain microarrays, to identify novel readers for histone H2Aub1 and H2Bub1, 
and H3TM K4me3, respectively. 
 
Based on Chapters 4 and 5, protein domain microarray is a high-throughput screening 
platform that can probe various peptide probes harboring different PTMs for novel interactions 
with varying effector modules. At the same time, there are two main limitations of protein 
domain microarrays compared to the tandem affinity purification-mass spectrometry (TAP-
MS) approach.  
 
The first limitation is that protein domain microarrays require prior knowledge of reader 
domains, limiting novel interactions within the domains arrayed on the microchips and missing 
potential readers that haven't been previously characterized. For example, RSF1, an 
H2Aub1-specific reader identified using a TAP-MS approach, contains a previously 
uncharacterized ubiquitin-binding motif (Zhang et al., 2017b).  
 
The second limitation is that most probes used with protein domain arrays are peptide probes 
that are prone to false-positive interactions. As both the peptide probes and protein domains 
on the microarrays are short fragments of full-length proteins, the identified novel interactions 
need to be carefully validated using in vitro and in vivo assays. For instance, in Chapter 4, 
HRS/HGS UIM domain was first identified as an H2Aub1-specific reader but didn't interact 
with the full-length H2Aub1 from the histone extracts, thus excluded from the following studies. 
In Chapter 5, I discovered several novel interactions between K4me3 H3TM peptides and 
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PHD fingers. After validation using pull-down assays, VRK1 K4me3-PHF2 PHD interaction 
was the most robust one, thus chosen for subsequent studies.  
 
In addition, interactions that are not relatively strong (weaker than 30-50 µM KD) are not 
detected on the array. These weaker interactions can often be identified by the pull-down 
approaches. For example, our Bromo-domain microarray has difficulty detecting specific 
interactions that are readily identified by the pull-down approaches. Finally, most of the protein 
domains we have arrayed are generated in isolation, and not linked to any other domain that 
may occur in close linear proximity or even in the tight association through a protein complex. 
As a consequence, we lose the ability to identify multivalent PTM engagement. This is an 
emerging theme in the chromatin field, which unfortunately cannot be addressed by our arrays 
that generally do not contain more than one domain per spot. 
 
There are a large number of different types of protein domains, and while a number of these 
domain types have been developed and used on array platforms, there are many more 
domain families that can be isolated, expressed as recombinant proteins and arrayed onto 
slides for detailed comparative analysis. I will highlight a few new directions below. 
 
Develop DNA and RNA-binding protein domain arrays: A huge class of untapped protein 
domains belongs to domain families that bind nucleic acids, either DNA or RNA. In the former 
case, these primarily involve domains found in transcription factors (Garvie and Wolberger, 
2001, Siggers and Gordan, 2014), and in the latter case, these are domains involved in 
splicing regulation and RNA shuttling (Lunde et al., 2007, Castello et al., 2016). There is also 
an emerging class of domains that bind both RNA and DNA (Hudson and Ortlund, 2014). 
These types of nucleic acid binding domain arrays hold the promise of not only identifying 
sequence-specific recognition protein modules, but also discovering selective readers of 
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modified DNA and RNA, and proteins that could bind double stranded RNA, single stranded 
DNA and RNA/DNA hybrids.  
 
Develop Phospholipid-binding protein domain arrays: Phospholipids and their reading 
proteins are essential components in signal transduction, such as protein translocation and 
lipid modification, upon stimulation of cell surface receptors. Major phospholipids in 
mammalian membranes are phosphotidylserine, phosphatidic acid and phosphatidylinositol. 
Phosphatidylinositol can be phosphorylated at the 3-, 4- and/or 5- positions to generate 
phosphoinositides. The composition of phospholipids depends on cell type and is tightly 
regulated. There are more than ten phospholipid-binding domains (Lemmon, 2008). Like 
protein-protein interactions, multiple domains in the same protein can cooperate with each 
other to facilitate membrane bindings. Therefore, it is important to determine the binding 
affinity of a phospholipid-domain pair and avidity effects of multivalent multi-domain 
interactions. By arraying single and tandem phospholipid binding domains, phospholipid-
binding domain arrays have the potential to dissect this sophisticated combinatorial “code”. 
 
Develop ADP-ribose binding domain arrays: Poly(ADP-ribosyl)ation (PARylation) is an 
important PTM involved in chromatin dynamics, genome stability maintenance, transcription, 
cell metabolism and development (Teloni and Altmeyer, 2016). There are four major PAR-
binding modules: PAR binding motif (PBM), Poly(ADP-Ribose)-binding Zinc Finger (PBZ), 
WWE domain, and macrodomain (Barkauskaite et al., 2013). ADP-ribose binding domain 
arrays will be promising in the identification of novel PARylation-dependent protein-protein 
interactions. The difficulty here will be the development of biotinylated PAR probes to 




In chapter 4 of this dissertation, I identified the PLAA PFU domain as a potential H2Bub1-
specific effector module using a ubiquitin-binding domain array. However, the PLAA-H2Bub1 
interaction may require additional factors for chromatin binding because the PFU domain 
specifically binds H2Bub1 from histone extracts but this does not translate into binding to 
nucleosomal recombinant H2Bub1. PTMs on the ubiquitin moiety of H2Bub1 could potentially 
contribute to the differences between endogenous H2Bub1 protein and recombinant H2Bub1 
nucleosomes.  
 
Endogenous H2Bub1 might harbor additional PTMs on the ubiquitin moiety, such as 
acetylation and phosphorylation, which regulate ubiquitin's conformation and binding 
characteristics (Ohtake et al., 2015, Kondapalli et al., 2012, Kane et al., 2014, Wauer et al., 
2015, Aguirre et al., 2017, Swaney et al., 2015, Dong et al., 2017, Walser et al., 2020). 
Acetylation of ubiquitin at K6 (K6ac) inhibits elongation of the K11-, K48-, and K63-linked 
polyubiquitin chains (Ohtake et al., 2015). Gel regions covering monoubiquitinated histones 
were analyzed by LC-MS, identifying Histone H2A and H2B are substrates for acetyl-
ubiquitinations, K6ac, and K48ac (Ohtake et al., 2015). Expression of K6Q (K6ac mimetic) 
ubiquitin increased H2Bub1 levels while that of K6R (non-acetylable) ubiquitin decreased 
H2Bub1 levels. Though there is no direct link between ubiquitin acetylation and H2Bub1 
stability, the data suggests that H2Bub1 and H2Aub1 are subject to an additional layer of 
regulation by ubiquitin acetylation, especially in the context of active transcription, which is 
marked by H2Bub1 and high chromatin acetylation activity.  
 
Similarly, ubiquitin phosphorylations at S65 (S65p Ub) and T12 (T12p Ub) modulate protein-
protein interactions and downstream functions. Mediated by PINK1, S65p Ub functions as an 
allosteric activator for Parkin (Kondapalli et al., 2012, Kane et al., 2014, Wauer et al., 2015, 
Aguirre et al., 2017). The latter is an E3 ligase that orchestrates the turnover of damaged 
 
 88 
mitochondria through mitophagy. Additionally, S65 phosphorylation allows ubiquitin to adopt 
two conformations in solution, a retracted state and a relaxed state (Dong et al., 2017, Swaney 
et al., 2015). The balance of these two states is pH-dependent, suggesting that S65 Ub might 
function in a location-specific manner, as pHs vary between separate cellular compartments 
(Casey et al., 2010).  
A recent study found that T12p Ub on histone H2AK15ub is a novel histone mark that 
regulates DNA damage response (Walser et al., 2020). 53BP1 is an H2AK15ub-specific 
effector upon DNA damage that recruits other protein complexes to the DNA damage sites 
(Fradet-Turcotte et al., 2013). T12p Ub on H2AK12ub blocks 53BP1's chromatin association 
by preventing its binding to H2AK15ub. In addition, it is possible that the T12p Ub may serve 
as a docking site for an effector molecule that harbors a BRCT or FHA domain (two domain 
types that read pT/pS motifs). Indeed, preliminary data from our lab has identified one such 
reader. 
 
All the above findings suggest that histone ubiquitination marks are subject to further 
modifications that orchestrate the conformation and interaction with effector modules. The 
next step is to characterize the H2Bub1 histone pulled down using the PLAA PFU domain and 
look for novel modifications on the ubiquitin moiety.  
 
Accumulation of a 15 kDa Ub-like protein in PLAA knockout cells 
I observed the accumulation of a 15 kDa band that can be recognized by the anti-Ubiquitin 
antibody in PLAA KO cells (Figure 10). One way to identify this protein is to analyze the gel 
bands at the 15 kDa regions by LC-MS, looking for highly abundant proteins in PLAA KO cells 




After ruling out the protein to be K48- and K63-linked di-ubiquitin, RPS27A, and ISG15, there 
is one last possible candidate, K29-linked di-ubiquitin. However, there are no commercially 
available antibodies against K29-Ub. Yu et al. recently described a synthetic antibody 
fragment that recognizes K29-Ub (Yu et al., 2020). Immunofluorescence showed K29-ub co-
localizes with VCP and the 20S proteasome. More importantly, K29-ub is enriched around the 
midbody in telophase, the patterns of which are similar to that of PLAA observed in my current 
study (data not shown). 
Given that Doa1 is a K29-Ub binder, PLAA might also bind K29-Ub chains and process them 
into mono-ubiquitin, which would explain the accumulation of the 15 kDa upon PLAA depletion. 
 
This hypothesis could be tested either by LC-MS as described above or overexpression of 
K29R and WT ubiquitin in PLAA KO cells. Alternatively, we could reach out to Yu et al. to 
request their K29-Ub specific antibody fragment. 
 
PLAA's recruitment to the DNA damage sites. 
Together with 53BP1 and γH2AX, PLAA is localized to the laser irradiation-induced DNA 
damage sites (Figure 12), suggesting PLAA's function in DDR. Notably, H2Bub1 depletion 
was observed at DNA damage sites. The current study could not determine whether PLAA 
recruitment and H2Bub1 removal are related to each other.  
 
As shown in this study and previously published work, PLAA interacts with VCP (Decottignies 
et al., 2004, Ghislain et al., 1996, Ogiso et al., 2004, Mullally et al., 2006). VCP is also involved 
in DNA damage response. VCP and its two cofactors, UFD1 and NPL4, mediate the extraction 
of ubiquitinated L3MBTL1 from H4K20me2 at DSBs, unmasking this mark for efficient 53BP1 




The PLAA-VCP complex may function in a similar way by disengaging ubiquitinated proteins 
from DSBs. Considering that we observe the depletion of H2Bub1 at DSBs (Figure 12B), 
H2Bub1 is potentially one of the ubiquitinated substrates removed by the PLAA-VCP complex. 
More work is needed to test this hypothesis. 
 
I propose three experiments to test these hypotheses: 1) Examine whether the recruitment of 
53BP1 recruitment and depletion  of H2Bub1 at DNA damage sites are defective in PLAA KO 
cells. 2) Rescue PLAA KO cells with PLAA truncations to map which domain(s) that is(are) 
required for PLAA enrichment at DSBs. 3) Identify the PLAA-interacting protein complex after 
DNA damage by LC-MS. 
 
In summary, the study in Chapter 4 identified PLAA as a potential H2Bub1-specific reader. I 
discovered the recruitment of PLAA recruited to the DNA damage sites and ubiquitin-related 
phenotypes in PLAA knockout cells, including reduced H2Aub1 and H2Bub1 and 
accumulation of a 15 kDa ubiquitin-like protein. Though additional work is needed, PLAA is 
possibly the first H2Bub1-specific effector protein.  
 
In Chapter 5 of this dissertation, I proposed the concept of histone H3 N-terminal mimicry and 
provided in vitro biochemical evidence that H3TM N-terminal K4me3 serves as a molecular 
switch that engage different protein interaction networks. These findings may dramatically 
expand the scope of functions that have been bestowed on methyl-effector proteins and the 
NuRD complex beyond the original histone code hypothesis by providing evidence that PHD 
fingers (and the Tudor domain of SPIN1) recognize not only histone proteins, but also non-




For these findings to be relevant, they of course need to also occur in cells and in vivo. 
However, we did not find direct evidence for the existence of the H3TM-K4me3 methylation 
state in vivo. This is not through lack of trying. First, using MS (Table 6), we were unable to 
map the N-terminal PTMs for all six tested H3TM candidates, because, like histone H3, the 
H3TMs are enriched for lysine or arginine residues in the vicinity of the K4 residue, generating 
tryptic peptides that are often very short and incompatible with MS analysis. Direct evidence 
for the occurrence of H3TM K4me3 will likely come from middle-/top-down mass spectrometry 
studies (Sidoli and Garcia, 2017). Second, we developed methyl-specific antibodies to K4me3 
sites on VRK1, BCL11B, TSHZ1 and MEF2C. While these antibodies selectively recognize 
the K4me3 peptides, and not the K4me0 peptides, in dot-blot assays, they were unable to 
detect these three endogenous H3TMs. This could be due to a number of reasons: 1) the 
antibodies are just bad; 2) the H4me3 mark occurs at very low levels, which makes it difficult 
for the antibodies to detect; and 3) the H4me3 mark on four H3TMs may be cell-type specific, 
tissue specific, cell-cycle specific, or development specific, and we have missed them.  
 
VRK1 is a nuclear kinase that regulates chromatin compaction in the G2/M phase (Valbuena 
et al., 2008, Jeong et al., 2013, Kang et al., 2007). I investigated whether the VRK1-K4me3, 
and the subsequent interaction with PHF2, could be related to VRK1's function in cell cycle 
regulation. However, there were no K4me3 signals or PHF2 interaction detected during mitotic 
arrest (Figure 23). Proteins often have functions that are yet to be discovered, limiting our 
understanding of the functional significance of protein-protein interactions beyond their 
classical roles. For instance, DNA ligase 1 (LIG1) K126me2/me3 has recently been identified 
as a novel ligand for the tandem Tudor domain of ubiquitin-like with PHD and RING finger 
domains 1 (UHRF1) using the same methyl reader domain microarray in Chapter 5 (Vaughan 
et al., 2020). LIG1 K126me2/me3 and H3K9me2/me3 compete for UHRF1 interactions. 
However, UHRF1's interactions with H3K9 and LIG1 didn't affect UHRF1's function in 
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maintaining cancer cell DNA methylation levels, the most well-characterized function of 
UHRF1. UHRF1's functions as a non-histone methyl-lysine reader remain to be uncovered. 
 
Although the cellular context of K4me3 remains unknown, the N-termini of H3TMs are 
disordered (https://iupred2a.elte.hu/) as is the H3 N-terminus, implying that the N-terminal 
regions need to be stabilized by PTMs or by interacting with binding partners (Bah and 
Forman-Kay, 2016). Indeed, H3TMs with unmodified N-terminal tails mimic unmodified 
histone H3. Several of the 48 H3TM candidates interact with the repressive NuRD complex, 
in their unmethylated state (Lauberth and Rauchman, 2006, Hong et al., 2005, Svensson et 
al., 2000, Dubuissez et al., 2016b, Moody et al., 2018, Cismasiu et al., 2005, Xu et al., 2013). 
Interestingly, the NuRD complex also recognizes the unmodified histone H3 N-terminus, but 
this interaction is disrupted by K4 trimethylation (Allen et al., 2013, Zegerman et al., 2002). 
K4me3 prohibits the chromatin-association of the repressive NuRD complex regulating local 
chromatin status to facilitate transcriptional activation. Among the 48 candidate proteins, 
Sall1/2/3/4, Fog1/2, and BCL11A/B are known to interact with the NuRD complex via their N-
termini, repressing target gene expressions (Lauberth and Rauchman, 2006, Hong et al., 
2005, Svensson et al., 2000, Dubuissez et al., 2016b, Moody et al., 2018, Cismasiu et al., 
2005, Xu et al., 2013). However, the mechanism by which these interactions are turned off 
remains unknown. Among the seven candidates that were used to probe the protein domain 
microarray (Figure 3), VRK1 K4me1, MEF2C K4ac, TSHZ1 K4ac, and BCL11B S2ph have 
been identified in various mass spectrometry studies (Wu et al., 2015, Angelelli et al., 2008, 
Dubuissez et al., 2016a, Schwer et al., 2009). Notably, BCL11B serine 2 phosphorylation has 
been shown to negatively regulate BCL11B’s interaction with the NuRD complex (Dubuissez 
et al., 2016b). Given that the N-terminal tail of histone H3 is heavily modified by various PTMs, 
such as phosphorylation, methylation, and acetylation, it is likely that the N-termini of these 
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H3TM proteins are also subject to PTMs that positively or negatively regulate their ability to 
interact with recognition modules.  
 
We have proposed a model that H3TMs bind the repressive NuRD complex in their 
unmethylated (K4me0) state, which is already well established, and in their K4me3 state these 
same H3TMs directly recruit effectors (protein that harbor PHD figures and Tudor domains) 
that have transcriptional activator activity (Figure 24). In cases where the binding affinity of 
the effector is greater for the H3TM than that for H3K4me3, these effectors may already reside 
on active chromatin and then be transferred to the H3TM. If the binding affinities are reversed 
(higher for H3K4me3 than H3TM-Kme3) then the H3TM may “deliver” the effector to chromatin. 
 
A search for proteins that harbor N-termini with sequence similarity to histone H3 identified 
striking enrichment (5-fold) of proteins with chromatin binding functions (Figure 14). Many of 
these H3TM proteins have already be shown to interact with the NuRD transcriptional 
repressor complex in their unmethylated states. We tested 7 of these methylated H3TMs for 
their ability to interact with known histone H3K4me3 binders, and they all do, to varying 
degrees. We thus hypothesize that the 48 H3TMs that we identified will be a major class of 





Figure 24. Regulation of H3TMs’ interaction networks by K4me3. Proteins containing 
PHD or Tudor domains often recognize the Histone H3K4me3, an active transcription mark, 
and recruit associating activator protein complex (AC) to the chromatin. Repressor complex, 
such as NuRD, interacts with chromatin by recognizing the unmodified Histone H3 tail. When 
unmodified at K4 sites, H3TMs interact with the NuRD complex. K4me3 on H3TMs 
disengages their interactions with the NuRD complex and turns on their interactions with AC 
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